CA2450205A1 - Aminediols for the treatment of alzheimer's disease - Google Patents
Aminediols for the treatment of alzheimer's disease Download PDFInfo
- Publication number
- CA2450205A1 CA2450205A1 CA002450205A CA2450205A CA2450205A1 CA 2450205 A1 CA2450205 A1 CA 2450205A1 CA 002450205 A CA002450205 A CA 002450205A CA 2450205 A CA2450205 A CA 2450205A CA 2450205 A1 CA2450205 A1 CA 2450205A1
- Authority
- CA
- Canada
- Prior art keywords
- amino
- alkyl
- methyl
- methylsulfonyl
- carbonyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 208000024827 Alzheimer disease Diseases 0.000 title claims abstract description 78
- 238000011282 treatment Methods 0.000 title claims abstract description 37
- 150000001875 compounds Chemical class 0.000 claims abstract description 297
- 238000000034 method Methods 0.000 claims abstract description 105
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 60
- 201000010099 disease Diseases 0.000 claims abstract description 55
- -1 -C1-C3 alkoxy Chemical group 0.000 claims description 284
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 195
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 194
- 229910052736 halogen Inorganic materials 0.000 claims description 125
- 150000002367 halogens Chemical class 0.000 claims description 118
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 100
- 125000000217 alkyl group Chemical group 0.000 claims description 78
- 125000003118 aryl group Chemical group 0.000 claims description 69
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 63
- 125000000623 heterocyclic group Chemical group 0.000 claims description 50
- 125000004663 dialkyl amino group Chemical group 0.000 claims description 49
- 125000001072 heteroaryl group Chemical group 0.000 claims description 45
- 150000003839 salts Chemical class 0.000 claims description 40
- 125000000304 alkynyl group Chemical group 0.000 claims description 37
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 36
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 36
- 206010012289 Dementia Diseases 0.000 claims description 33
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 31
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 claims description 28
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 25
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 24
- 238000004519 manufacturing process Methods 0.000 claims description 24
- 208000005145 Cerebral amyloid angiopathy Diseases 0.000 claims description 22
- 208000010877 cognitive disease Diseases 0.000 claims description 22
- 208000027061 mild cognitive impairment Diseases 0.000 claims description 22
- 230000003412 degenerative effect Effects 0.000 claims description 20
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 18
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims description 17
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 17
- 125000003545 alkoxy group Chemical group 0.000 claims description 16
- HEBKCHPVOIAQTA-NGQZWQHPSA-N d-xylitol Chemical compound OC[C@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-NGQZWQHPSA-N 0.000 claims description 16
- FBPFZTCFMRRESA-UHFFFAOYSA-N hexane-1,2,3,4,5,6-hexol Chemical compound OCC(O)C(O)C(O)C(O)CO FBPFZTCFMRRESA-UHFFFAOYSA-N 0.000 claims description 16
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 16
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 15
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 15
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 claims description 14
- 201000010374 Down Syndrome Diseases 0.000 claims description 14
- 206010044688 Trisomy 21 Diseases 0.000 claims description 14
- 229910052739 hydrogen Inorganic materials 0.000 claims description 14
- 239000001257 hydrogen Substances 0.000 claims description 13
- 208000018282 ACys amyloidosis Diseases 0.000 claims description 12
- 208000007487 Familial Cerebral Amyloid Angiopathy Diseases 0.000 claims description 12
- 208000032849 Hereditary cerebral hemorrhage with amyloidosis Diseases 0.000 claims description 12
- 239000003814 drug Substances 0.000 claims description 11
- 125000002877 alkyl aryl group Chemical group 0.000 claims description 10
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 10
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 10
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 10
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 10
- 230000002792 vascular Effects 0.000 claims description 10
- 208000018737 Parkinson disease Diseases 0.000 claims description 9
- 125000005213 alkyl heteroaryl group Chemical group 0.000 claims description 9
- 230000001054 cortical effect Effects 0.000 claims description 9
- 230000007850 degeneration Effects 0.000 claims description 9
- 201000002212 progressive supranuclear palsy Diseases 0.000 claims description 9
- 229910052717 sulfur Inorganic materials 0.000 claims description 9
- 125000004432 carbon atom Chemical group C* 0.000 claims description 8
- 125000005842 heteroatom Chemical group 0.000 claims description 8
- 229910052760 oxygen Inorganic materials 0.000 claims description 8
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims description 7
- 210000004558 lewy body Anatomy 0.000 claims description 7
- 125000004400 (C1-C12) alkyl group Chemical group 0.000 claims description 6
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 6
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims description 6
- 229910052799 carbon Inorganic materials 0.000 claims description 6
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 6
- 125000006727 (C1-C6) alkenyl group Chemical group 0.000 claims description 5
- 125000006620 amino-(C1-C6) alkyl group Chemical group 0.000 claims description 5
- 125000004429 atom Chemical group 0.000 claims description 5
- 230000002265 prevention Effects 0.000 claims description 5
- 125000006710 (C2-C12) alkenyl group Chemical group 0.000 claims description 4
- 125000006711 (C2-C12) alkynyl group Chemical group 0.000 claims description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 4
- 125000004568 thiomorpholinyl group Chemical group 0.000 claims description 4
- 125000002853 C1-C4 hydroxyalkyl group Chemical group 0.000 claims description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 3
- 150000001721 carbon Chemical group 0.000 claims description 3
- 125000004438 haloalkoxy group Chemical group 0.000 claims description 3
- RCCPEORTSYDPMB-UHFFFAOYSA-N hydroxy benzenecarboximidothioate Chemical compound OSC(=N)C1=CC=CC=C1 RCCPEORTSYDPMB-UHFFFAOYSA-N 0.000 claims description 3
- 125000002757 morpholinyl group Chemical group 0.000 claims description 3
- 125000004193 piperazinyl group Chemical group 0.000 claims description 3
- 125000003386 piperidinyl group Chemical group 0.000 claims description 3
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 3
- 125000001422 pyrrolinyl group Chemical group 0.000 claims description 3
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims description 2
- VOTQNKMWMRRTNF-UHFFFAOYSA-N 1-n-(3,4-dihydroxy-1-phenylnon-8-yn-2-yl)-5-methyl-3-n,3-n-dipropylbenzene-1,3-dicarboxamide Chemical compound CCCN(CCC)C(=O)C1=CC(C)=CC(C(=O)NC(CC=2C=CC=CC=2)C(O)C(O)CCCC#C)=C1 VOTQNKMWMRRTNF-UHFFFAOYSA-N 0.000 claims description 2
- HITDTRFWXBCZJF-UHFFFAOYSA-N 1-n-(3,4-dihydroxy-1-phenylnonan-2-yl)-3-n,3-n-dipropylbenzene-1,3,5-tricarboxamide Chemical compound C=1C(C(N)=O)=CC(C(=O)N(CCC)CCC)=CC=1C(=O)NC(C(O)C(O)CCCCC)CC1=CC=CC=C1 HITDTRFWXBCZJF-UHFFFAOYSA-N 0.000 claims description 2
- ALCHLYSYYJLTFT-UHFFFAOYSA-N 1-n-(3,4-dihydroxy-1-phenylnonan-2-yl)-5-methyl-3-n,3-n-dipropylbenzene-1,3-dicarboxamide Chemical compound C=1C(C)=CC(C(=O)N(CCC)CCC)=CC=1C(=O)NC(C(O)C(O)CCCCC)CC1=CC=CC=C1 ALCHLYSYYJLTFT-UHFFFAOYSA-N 0.000 claims description 2
- AAVKAKMEABDNQS-UHFFFAOYSA-N 1-n-(3,4-dihydroxy-1-phenyloctan-2-yl)-3-n,3-n-dipropylbenzene-1,3,5-tricarboxamide Chemical compound C=1C(C(N)=O)=CC(C(=O)N(CCC)CCC)=CC=1C(=O)NC(C(O)C(O)CCCC)CC1=CC=CC=C1 AAVKAKMEABDNQS-UHFFFAOYSA-N 0.000 claims description 2
- IYXJKKSOTIEAPD-UHFFFAOYSA-N 1-n-(3,4-dihydroxy-1-phenyloctan-2-yl)-5-methyl-3-n,3-n-dipropylbenzene-1,3-dicarboxamide Chemical compound C=1C(C)=CC(C(=O)N(CCC)CCC)=CC=1C(=O)NC(C(O)C(O)CCCC)CC1=CC=CC=C1 IYXJKKSOTIEAPD-UHFFFAOYSA-N 0.000 claims description 2
- PXEPFHWUNYEJHE-UHFFFAOYSA-N 1-n-(3,4-dihydroxy-1-pyridin-4-ylnon-8-yn-2-yl)-3-n,3-n-dipropylbenzene-1,3,5-tricarboxamide Chemical compound CCCN(CCC)C(=O)C1=CC(C(N)=O)=CC(C(=O)NC(CC=2C=CN=CC=2)C(O)C(O)CCCC#C)=C1 PXEPFHWUNYEJHE-UHFFFAOYSA-N 0.000 claims description 2
- WPAMKXTYYVGJER-UHFFFAOYSA-N 1-n-(3,4-dihydroxy-1-pyridin-4-ylnon-8-yn-2-yl)-5-methyl-3-n,3-n-dipropylbenzene-1,3-dicarboxamide Chemical compound CCCN(CCC)C(=O)C1=CC(C)=CC(C(=O)NC(CC=2C=CN=CC=2)C(O)C(O)CCCC#C)=C1 WPAMKXTYYVGJER-UHFFFAOYSA-N 0.000 claims description 2
- FQTFDCDCWYHFGN-UHFFFAOYSA-N 1-n-(3,4-dihydroxy-1-pyridin-4-ylnonan-2-yl)-3-n,3-n-dipropylbenzene-1,3,5-tricarboxamide Chemical compound C=1C(C(N)=O)=CC(C(=O)N(CCC)CCC)=CC=1C(=O)NC(C(O)C(O)CCCCC)CC1=CC=NC=C1 FQTFDCDCWYHFGN-UHFFFAOYSA-N 0.000 claims description 2
- BDPAFFSKXNRJTJ-UHFFFAOYSA-N 1-n-(3,4-dihydroxy-1-pyridin-4-ylnonan-2-yl)-5-methyl-3-n,3-n-dipropylbenzene-1,3-dicarboxamide Chemical compound C=1C(C)=CC(C(=O)N(CCC)CCC)=CC=1C(=O)NC(C(O)C(O)CCCCC)CC1=CC=NC=C1 BDPAFFSKXNRJTJ-UHFFFAOYSA-N 0.000 claims description 2
- WZCUDEDCAQCUCE-UHFFFAOYSA-N 1-n-(3,4-dihydroxy-1-pyridin-4-yloctan-2-yl)-3-n,3-n-dipropylbenzene-1,3,5-tricarboxamide Chemical compound C=1C(C(N)=O)=CC(C(=O)N(CCC)CCC)=CC=1C(=O)NC(C(O)C(O)CCCC)CC1=CC=NC=C1 WZCUDEDCAQCUCE-UHFFFAOYSA-N 0.000 claims description 2
- ORAIVINDYDGYIZ-UHFFFAOYSA-N 1-n-(3,4-dihydroxy-1-pyridin-4-yloctan-2-yl)-5-methyl-3-n,3-n-dipropylbenzene-1,3-dicarboxamide Chemical compound C=1C(C)=CC(C(=O)N(CCC)CCC)=CC=1C(=O)NC(C(O)C(O)CCCC)CC1=CC=NC=C1 ORAIVINDYDGYIZ-UHFFFAOYSA-N 0.000 claims description 2
- DWNXUJOGMRSHQU-UHFFFAOYSA-N 1-n-(5-cyano-3,4-dihydroxy-1-phenylpentan-2-yl)-3-n,3-n-dipropylbenzene-1,3,5-tricarboxamide Chemical compound CCCN(CCC)C(=O)C1=CC(C(N)=O)=CC(C(=O)NC(CC=2C=CC=CC=2)C(O)C(O)CC#N)=C1 DWNXUJOGMRSHQU-UHFFFAOYSA-N 0.000 claims description 2
- LZGBDIBWWSFJNJ-UHFFFAOYSA-N 1-n-(5-cyano-3,4-dihydroxy-1-pyridin-4-ylpentan-2-yl)-5-methyl-3-n,3-n-dipropylbenzene-1,3-dicarboxamide Chemical compound CCCN(CCC)C(=O)C1=CC(C)=CC(C(=O)NC(CC=2C=CN=CC=2)C(O)C(O)CC#N)=C1 LZGBDIBWWSFJNJ-UHFFFAOYSA-N 0.000 claims description 2
- SSFQIVVDFOMWBB-UHFFFAOYSA-N 1-n-(6-cyano-3,4-dihydroxy-1-phenylhexan-2-yl)-5-methyl-3-n,3-n-dipropylbenzene-1,3-dicarboxamide Chemical compound CCCN(CCC)C(=O)C1=CC(C)=CC(C(=O)NC(CC=2C=CC=CC=2)C(O)C(O)CCC#N)=C1 SSFQIVVDFOMWBB-UHFFFAOYSA-N 0.000 claims description 2
- LLXIOCMEBLSORL-UHFFFAOYSA-N 1-n-(7-cyano-3,4-dihydroxy-1-phenylheptan-2-yl)-5-methyl-3-n,3-n-dipropylbenzene-1,3-dicarboxamide Chemical compound CCCN(CCC)C(=O)C1=CC(C)=CC(C(=O)NC(CC=2C=CC=CC=2)C(O)C(O)CCCC#N)=C1 LLXIOCMEBLSORL-UHFFFAOYSA-N 0.000 claims description 2
- AOSMPTJYBUOPRJ-UHFFFAOYSA-N 1-n-(7-cyano-3,4-dihydroxy-1-pyridin-4-ylheptan-2-yl)-5-methyl-3-n,3-n-dipropylbenzene-1,3-dicarboxamide Chemical compound CCCN(CCC)C(=O)C1=CC(C)=CC(C(=O)NC(CC=2C=CN=CC=2)C(O)C(O)CCCC#N)=C1 AOSMPTJYBUOPRJ-UHFFFAOYSA-N 0.000 claims description 2
- RWJSXDABPVWKTG-GMQQYTKMSA-N 1-n-[(2s,3r,4s)-1-(3,5-difluorophenyl)-3,4-dihydroxyoctan-2-yl]-5-methyl-3-n,3-n-dipropylbenzene-1,3-dicarboxamide Chemical compound C([C@@H]([C@@H](O)[C@@H](O)CCCC)NC(=O)C=1C=C(C=C(C)C=1)C(=O)N(CCC)CCC)C1=CC(F)=CC(F)=C1 RWJSXDABPVWKTG-GMQQYTKMSA-N 0.000 claims description 2
- IYXJKKSOTIEAPD-GMQQYTKMSA-N 1-n-[(2s,3r,4s)-3,4-dihydroxy-1-phenyloctan-2-yl]-5-methyl-3-n,3-n-dipropylbenzene-1,3-dicarboxamide Chemical compound C([C@@H]([C@@H](O)[C@@H](O)CCCC)NC(=O)C=1C=C(C=C(C)C=1)C(=O)N(CCC)CCC)C1=CC=CC=C1 IYXJKKSOTIEAPD-GMQQYTKMSA-N 0.000 claims description 2
- UWSGMOGLUPCWSD-UHFFFAOYSA-N 1-n-[1-(3,5-difluorophenyl)-3,4-dihydroxynon-8-yn-2-yl]-3-n,3-n-dipropylbenzene-1,3,5-tricarboxamide Chemical compound CCCN(CCC)C(=O)C1=CC(C(N)=O)=CC(C(=O)NC(CC=2C=C(F)C=C(F)C=2)C(O)C(O)CCCC#C)=C1 UWSGMOGLUPCWSD-UHFFFAOYSA-N 0.000 claims description 2
- YHNUDRUAWHFWDB-UHFFFAOYSA-N 1-n-[1-(3,5-difluorophenyl)-3,4-dihydroxynon-8-yn-2-yl]-5-methyl-3-n,3-n-dipropylbenzene-1,3-dicarboxamide Chemical compound CCCN(CCC)C(=O)C1=CC(C)=CC(C(=O)NC(CC=2C=C(F)C=C(F)C=2)C(O)C(O)CCCC#C)=C1 YHNUDRUAWHFWDB-UHFFFAOYSA-N 0.000 claims description 2
- WMDGYQCKMSZYOG-UHFFFAOYSA-N 1-n-[1-(3,5-difluorophenyl)-3,4-dihydroxynonan-2-yl]-5-methyl-3-n,3-n-dipropylbenzene-1,3-dicarboxamide Chemical compound C=1C(C)=CC(C(=O)N(CCC)CCC)=CC=1C(=O)NC(C(O)C(O)CCCCC)CC1=CC(F)=CC(F)=C1 WMDGYQCKMSZYOG-UHFFFAOYSA-N 0.000 claims description 2
- LZVSRTMEGVYLGF-UHFFFAOYSA-N 1-n-[1-(3,5-difluorophenyl)-3,4-dihydroxyoctan-2-yl]-3-n,3-n-dipropylbenzene-1,3,5-tricarboxamide Chemical compound C=1C(C(N)=O)=CC(C(=O)N(CCC)CCC)=CC=1C(=O)NC(C(O)C(O)CCCC)CC1=CC(F)=CC(F)=C1 LZVSRTMEGVYLGF-UHFFFAOYSA-N 0.000 claims description 2
- KUZDLJRJBFYMTC-UHFFFAOYSA-N 1-n-[3,4-dihydroxy-1-(4-hydroxyphenyl)non-8-yn-2-yl]-3-n,3-n-dipropylbenzene-1,3,5-tricarboxamide Chemical compound CCCN(CCC)C(=O)C1=CC(C(N)=O)=CC(C(=O)NC(CC=2C=CC(O)=CC=2)C(O)C(O)CCCC#C)=C1 KUZDLJRJBFYMTC-UHFFFAOYSA-N 0.000 claims description 2
- ZJWHWUVMSFIIDS-UHFFFAOYSA-N 1-n-[3,4-dihydroxy-1-(4-hydroxyphenyl)non-8-yn-2-yl]-5-methyl-3-n,3-n-dipropylbenzene-1,3-dicarboxamide Chemical compound CCCN(CCC)C(=O)C1=CC(C)=CC(C(=O)NC(CC=2C=CC(O)=CC=2)C(O)C(O)CCCC#C)=C1 ZJWHWUVMSFIIDS-UHFFFAOYSA-N 0.000 claims description 2
- FFWPOAJMONBVEC-UHFFFAOYSA-N 1-n-[3,4-dihydroxy-1-(4-hydroxyphenyl)nonan-2-yl]-3-n,3-n-dipropylbenzene-1,3,5-tricarboxamide Chemical compound C=1C(C(N)=O)=CC(C(=O)N(CCC)CCC)=CC=1C(=O)NC(C(O)C(O)CCCCC)CC1=CC=C(O)C=C1 FFWPOAJMONBVEC-UHFFFAOYSA-N 0.000 claims description 2
- MNTOBJNGQLGOEM-UHFFFAOYSA-N 1-n-[3,4-dihydroxy-1-(4-hydroxyphenyl)nonan-2-yl]-5-methyl-3-n,3-n-dipropylbenzene-1,3-dicarboxamide Chemical compound C=1C(C)=CC(C(=O)N(CCC)CCC)=CC=1C(=O)NC(C(O)C(O)CCCCC)CC1=CC=C(O)C=C1 MNTOBJNGQLGOEM-UHFFFAOYSA-N 0.000 claims description 2
- XRDRGVGVJHIFRA-UHFFFAOYSA-N 1-n-[3,4-dihydroxy-1-(4-hydroxyphenyl)octan-2-yl]-3-n,3-n-dipropylbenzene-1,3,5-tricarboxamide Chemical compound C=1C(C(N)=O)=CC(C(=O)N(CCC)CCC)=CC=1C(=O)NC(C(O)C(O)CCCC)CC1=CC=C(O)C=C1 XRDRGVGVJHIFRA-UHFFFAOYSA-N 0.000 claims description 2
- GCKMFOCAAVSDHT-UHFFFAOYSA-N 1-n-[3,4-dihydroxy-1-(4-hydroxyphenyl)octan-2-yl]-5-methyl-3-n,3-n-dipropylbenzene-1,3-dicarboxamide Chemical compound C=1C(C)=CC(C(=O)N(CCC)CCC)=CC=1C(=O)NC(C(O)C(O)CCCC)CC1=CC=C(O)C=C1 GCKMFOCAAVSDHT-UHFFFAOYSA-N 0.000 claims description 2
- WKQXXNSIQNTDHQ-UHFFFAOYSA-N 1-n-[5-cyano-1-(3,5-difluorophenyl)-3,4-dihydroxypentan-2-yl]-3-n,3-n-dipropylbenzene-1,3,5-tricarboxamide Chemical compound CCCN(CCC)C(=O)C1=CC(C(N)=O)=CC(C(=O)NC(CC=2C=C(F)C=C(F)C=2)C(O)C(O)CC#N)=C1 WKQXXNSIQNTDHQ-UHFFFAOYSA-N 0.000 claims description 2
- YJMNLGJZBOJSET-UHFFFAOYSA-N 1-n-[5-cyano-1-(3,5-difluorophenyl)-3,4-dihydroxypentan-2-yl]-5-methyl-3-n,3-n-dipropylbenzene-1,3-dicarboxamide Chemical compound CCCN(CCC)C(=O)C1=CC(C)=CC(C(=O)NC(CC=2C=C(F)C=C(F)C=2)C(O)C(O)CC#N)=C1 YJMNLGJZBOJSET-UHFFFAOYSA-N 0.000 claims description 2
- UGCJMVNJFWNPBL-UHFFFAOYSA-N 1-n-[5-cyano-3,4-dihydroxy-1-(4-hydroxyphenyl)pentan-2-yl]-3-n,3-n-dipropylbenzene-1,3,5-tricarboxamide Chemical compound CCCN(CCC)C(=O)C1=CC(C(N)=O)=CC(C(=O)NC(CC=2C=CC(O)=CC=2)C(O)C(O)CC#N)=C1 UGCJMVNJFWNPBL-UHFFFAOYSA-N 0.000 claims description 2
- SYOXZQFZLVFTSJ-UHFFFAOYSA-N 1-n-[5-cyano-3,4-dihydroxy-1-(4-hydroxyphenyl)pentan-2-yl]-5-methyl-3-n,3-n-dipropylbenzene-1,3-dicarboxamide Chemical compound CCCN(CCC)C(=O)C1=CC(C)=CC(C(=O)NC(CC=2C=CC(O)=CC=2)C(O)C(O)CC#N)=C1 SYOXZQFZLVFTSJ-UHFFFAOYSA-N 0.000 claims description 2
- SOTYKCOPLDKSEZ-UHFFFAOYSA-N 1-n-[6-cyano-3,4-dihydroxy-1-(4-hydroxyphenyl)hexan-2-yl]-3-n,3-n-dipropylbenzene-1,3,5-tricarboxamide Chemical compound CCCN(CCC)C(=O)C1=CC(C(N)=O)=CC(C(=O)NC(CC=2C=CC(O)=CC=2)C(O)C(O)CCC#N)=C1 SOTYKCOPLDKSEZ-UHFFFAOYSA-N 0.000 claims description 2
- HWVLPHLSQWMMCY-UHFFFAOYSA-N 1-n-[6-cyano-3,4-dihydroxy-1-(4-hydroxyphenyl)hexan-2-yl]-5-methyl-3-n,3-n-dipropylbenzene-1,3-dicarboxamide Chemical compound CCCN(CCC)C(=O)C1=CC(C)=CC(C(=O)NC(CC=2C=CC(O)=CC=2)C(O)C(O)CCC#N)=C1 HWVLPHLSQWMMCY-UHFFFAOYSA-N 0.000 claims description 2
- AHOBFZPTLKVJOP-UHFFFAOYSA-N 1-n-[7-cyano-1-(3,5-difluorophenyl)-3,4-dihydroxyheptan-2-yl]-5-methyl-3-n,3-n-dipropylbenzene-1,3-dicarboxamide Chemical compound CCCN(CCC)C(=O)C1=CC(C)=CC(C(=O)NC(CC=2C=C(F)C=C(F)C=2)C(O)C(O)CCCC#N)=C1 AHOBFZPTLKVJOP-UHFFFAOYSA-N 0.000 claims description 2
- QPVXVENZJINNGY-UHFFFAOYSA-N 1-n-[7-cyano-3,4-dihydroxy-1-(4-hydroxyphenyl)heptan-2-yl]-5-methyl-3-n,3-n-dipropylbenzene-1,3-dicarboxamide Chemical compound CCCN(CCC)C(=O)C1=CC(C)=CC(C(=O)NC(CC=2C=CC(O)=CC=2)C(O)C(O)CCCC#N)=C1 QPVXVENZJINNGY-UHFFFAOYSA-N 0.000 claims description 2
- MNJRFOQXRKWYNK-JIMJEQGWSA-N 5-bromo-1-n-[(2s,3r,4r)-1-(3,5-difluorophenyl)-3,4-dihydroxyoctan-2-yl]-3-n,3-n-dipropylbenzene-1,3-dicarboxamide Chemical compound C([C@@H]([C@@H](O)[C@H](O)CCCC)NC(=O)C=1C=C(C=C(Br)C=1)C(=O)N(CCC)CCC)C1=CC(F)=CC(F)=C1 MNJRFOQXRKWYNK-JIMJEQGWSA-N 0.000 claims description 2
- RJEBHTRBRCSTAU-ISJGIBHGSA-N 5-bromo-1-n-[(2s,3r,4r)-3,4-dihydroxy-6-methylsulfanyl-1-phenylhexan-2-yl]-3-n,3-n-dipropylbenzene-1,3-dicarboxamide Chemical compound CCCN(CCC)C(=O)C1=CC(Br)=CC(C(=O)N[C@@H](CC=2C=CC=CC=2)[C@@H](O)[C@H](O)CCSC)=C1 RJEBHTRBRCSTAU-ISJGIBHGSA-N 0.000 claims description 2
- 125000006539 C12 alkyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 2
- FQLOFJPZKGNMBN-UHFFFAOYSA-N n-(3,4-dihydroxy-1-phenylnon-8-yn-2-yl)-2-(methanesulfonamido)-1,3-oxazole-4-carboxamide Chemical compound O1C(NS(=O)(=O)C)=NC(C(=O)NC(CC=2C=CC=CC=2)C(O)C(O)CCCC#C)=C1 FQLOFJPZKGNMBN-UHFFFAOYSA-N 0.000 claims description 2
- PIZGCXNUIKRZSS-UHFFFAOYSA-N n-(3,4-dihydroxy-1-phenylnon-8-yn-2-yl)-2-(methanesulfonamido)-1,3-thiazole-4-carboxamide Chemical compound S1C(NS(=O)(=O)C)=NC(C(=O)NC(CC=2C=CC=CC=2)C(O)C(O)CCCC#C)=C1 PIZGCXNUIKRZSS-UHFFFAOYSA-N 0.000 claims description 2
- SFEPQHQILIEWBE-UHFFFAOYSA-N n-(3,4-dihydroxy-1-phenylnon-8-yn-2-yl)-2-[methyl(methylsulfonyl)amino]-1,3-oxazole-4-carboxamide Chemical compound O1C(N(C)S(C)(=O)=O)=NC(C(=O)NC(CC=2C=CC=CC=2)C(O)C(O)CCCC#C)=C1 SFEPQHQILIEWBE-UHFFFAOYSA-N 0.000 claims description 2
- UMOCORDYZKMACY-UHFFFAOYSA-N n-(3,4-dihydroxy-1-phenylnon-8-yn-2-yl)-2-[methyl(methylsulfonyl)amino]-1,3-thiazole-4-carboxamide Chemical compound S1C(N(C)S(C)(=O)=O)=NC(C(=O)NC(CC=2C=CC=CC=2)C(O)C(O)CCCC#C)=C1 UMOCORDYZKMACY-UHFFFAOYSA-N 0.000 claims description 2
- ZJNPPKUBLBYDRA-UHFFFAOYSA-N n-(3,4-dihydroxy-1-phenylnonan-2-yl)-2-(methanesulfonamido)-1,3-oxazole-4-carboxamide Chemical compound C=1OC(NS(C)(=O)=O)=NC=1C(=O)NC(C(O)C(O)CCCCC)CC1=CC=CC=C1 ZJNPPKUBLBYDRA-UHFFFAOYSA-N 0.000 claims description 2
- XSZPAWSHCBKYKT-UHFFFAOYSA-N n-(3,4-dihydroxy-1-phenylnonan-2-yl)-2-(methanesulfonamido)-1,3-thiazole-4-carboxamide Chemical compound C=1SC(NS(C)(=O)=O)=NC=1C(=O)NC(C(O)C(O)CCCCC)CC1=CC=CC=C1 XSZPAWSHCBKYKT-UHFFFAOYSA-N 0.000 claims description 2
- YOPVCAFJGNBJHO-UHFFFAOYSA-N n-(3,4-dihydroxy-1-phenylnonan-2-yl)-2-[methyl(methylsulfonyl)amino]-1,3-oxazole-4-carboxamide Chemical compound C=1OC(N(C)S(C)(=O)=O)=NC=1C(=O)NC(C(O)C(O)CCCCC)CC1=CC=CC=C1 YOPVCAFJGNBJHO-UHFFFAOYSA-N 0.000 claims description 2
- PRNFJRCIEUYMKP-UHFFFAOYSA-N n-(3,4-dihydroxy-1-phenyloctan-2-yl)-2-(methanesulfonamido)-1,3-oxazole-4-carboxamide Chemical compound C=1OC(NS(C)(=O)=O)=NC=1C(=O)NC(C(O)C(O)CCCC)CC1=CC=CC=C1 PRNFJRCIEUYMKP-UHFFFAOYSA-N 0.000 claims description 2
- RRMIBABTGXERQS-UHFFFAOYSA-N n-(3,4-dihydroxy-1-phenyloctan-2-yl)-2-(methanesulfonamido)-1,3-thiazole-4-carboxamide Chemical compound C=1SC(NS(C)(=O)=O)=NC=1C(=O)NC(C(O)C(O)CCCC)CC1=CC=CC=C1 RRMIBABTGXERQS-UHFFFAOYSA-N 0.000 claims description 2
- PFUFLTNHXQIMMF-UHFFFAOYSA-N n-(3,4-dihydroxy-1-phenyloctan-2-yl)-2-[methyl(methylsulfonyl)amino]-1,3-oxazole-4-carboxamide Chemical compound C=1OC(N(C)S(C)(=O)=O)=NC=1C(=O)NC(C(O)C(O)CCCC)CC1=CC=CC=C1 PFUFLTNHXQIMMF-UHFFFAOYSA-N 0.000 claims description 2
- PBYNVXJYJYHLNA-UHFFFAOYSA-N n-(3,4-dihydroxy-1-phenyloctan-2-yl)-2-[methyl(methylsulfonyl)amino]-1,3-thiazole-4-carboxamide Chemical compound C=1SC(N(C)S(C)(=O)=O)=NC=1C(=O)NC(C(O)C(O)CCCC)CC1=CC=CC=C1 PBYNVXJYJYHLNA-UHFFFAOYSA-N 0.000 claims description 2
- OUXIFDDPZRQVIH-UHFFFAOYSA-N n-(3,4-dihydroxy-1-pyridin-4-ylnon-8-yn-2-yl)-2-(methanesulfonamido)-1,3-oxazole-4-carboxamide Chemical compound O1C(NS(=O)(=O)C)=NC(C(=O)NC(CC=2C=CN=CC=2)C(O)C(O)CCCC#C)=C1 OUXIFDDPZRQVIH-UHFFFAOYSA-N 0.000 claims description 2
- ODBYAKDLFIHOPZ-UHFFFAOYSA-N n-(3,4-dihydroxy-1-pyridin-4-ylnon-8-yn-2-yl)-2-(methanesulfonamido)-1,3-thiazole-4-carboxamide Chemical compound S1C(NS(=O)(=O)C)=NC(C(=O)NC(CC=2C=CN=CC=2)C(O)C(O)CCCC#C)=C1 ODBYAKDLFIHOPZ-UHFFFAOYSA-N 0.000 claims description 2
- BRYIWUVIWJKGGB-UHFFFAOYSA-N n-(3,4-dihydroxy-1-pyridin-4-ylnon-8-yn-2-yl)-2-[methyl(methylsulfonyl)amino]-1,3-oxazole-4-carboxamide Chemical compound O1C(N(C)S(C)(=O)=O)=NC(C(=O)NC(CC=2C=CN=CC=2)C(O)C(O)CCCC#C)=C1 BRYIWUVIWJKGGB-UHFFFAOYSA-N 0.000 claims description 2
- DZEFMMSNFRNBMB-UHFFFAOYSA-N n-(3,4-dihydroxy-1-pyridin-4-ylnon-8-yn-2-yl)-2-[methyl(methylsulfonyl)amino]-1,3-thiazole-4-carboxamide Chemical compound S1C(N(C)S(C)(=O)=O)=NC(C(=O)NC(CC=2C=CN=CC=2)C(O)C(O)CCCC#C)=C1 DZEFMMSNFRNBMB-UHFFFAOYSA-N 0.000 claims description 2
- CBFLRZIVUDAMIV-UHFFFAOYSA-N n-(3,4-dihydroxy-1-pyridin-4-ylnonan-2-yl)-2-(methanesulfonamido)-1,3-oxazole-4-carboxamide Chemical compound C=1OC(NS(C)(=O)=O)=NC=1C(=O)NC(C(O)C(O)CCCCC)CC1=CC=NC=C1 CBFLRZIVUDAMIV-UHFFFAOYSA-N 0.000 claims description 2
- OERHBZQVAGVNAE-UHFFFAOYSA-N n-(3,4-dihydroxy-1-pyridin-4-ylnonan-2-yl)-2-[methyl(methylsulfonyl)amino]-1,3-oxazole-4-carboxamide Chemical compound C=1OC(N(C)S(C)(=O)=O)=NC=1C(=O)NC(C(O)C(O)CCCCC)CC1=CC=NC=C1 OERHBZQVAGVNAE-UHFFFAOYSA-N 0.000 claims description 2
- OLIWDSFQXZDABW-UHFFFAOYSA-N n-(3,4-dihydroxy-1-pyridin-4-ylnonan-2-yl)-2-[methyl(methylsulfonyl)amino]-1,3-thiazole-4-carboxamide Chemical compound C=1SC(N(C)S(C)(=O)=O)=NC=1C(=O)NC(C(O)C(O)CCCCC)CC1=CC=NC=C1 OLIWDSFQXZDABW-UHFFFAOYSA-N 0.000 claims description 2
- CSRLBACOQGOZHZ-UHFFFAOYSA-N n-(3,4-dihydroxy-1-pyridin-4-yloctan-2-yl)-2-(methanesulfonamido)-1,3-oxazole-4-carboxamide Chemical compound C=1OC(NS(C)(=O)=O)=NC=1C(=O)NC(C(O)C(O)CCCC)CC1=CC=NC=C1 CSRLBACOQGOZHZ-UHFFFAOYSA-N 0.000 claims description 2
- UKMVSXAZDSTTRU-UHFFFAOYSA-N n-(3,4-dihydroxy-1-pyridin-4-yloctan-2-yl)-2-(methanesulfonamido)-1,3-thiazole-4-carboxamide Chemical compound C=1SC(NS(C)(=O)=O)=NC=1C(=O)NC(C(O)C(O)CCCC)CC1=CC=NC=C1 UKMVSXAZDSTTRU-UHFFFAOYSA-N 0.000 claims description 2
- OGSUNNQDNMVEES-UHFFFAOYSA-N n-(3,4-dihydroxy-1-pyridin-4-yloctan-2-yl)-2-[methyl(methylsulfonyl)amino]-1,3-oxazole-4-carboxamide Chemical compound C=1OC(N(C)S(C)(=O)=O)=NC=1C(=O)NC(C(O)C(O)CCCC)CC1=CC=NC=C1 OGSUNNQDNMVEES-UHFFFAOYSA-N 0.000 claims description 2
- HHYWBSQWQBLDBQ-UHFFFAOYSA-N n-(3,4-dihydroxy-1-pyridin-4-yloctan-2-yl)-2-[methyl(methylsulfonyl)amino]-1,3-thiazole-4-carboxamide Chemical compound C=1SC(N(C)S(C)(=O)=O)=NC=1C(=O)NC(C(O)C(O)CCCC)CC1=CC=NC=C1 HHYWBSQWQBLDBQ-UHFFFAOYSA-N 0.000 claims description 2
- JWOVPOURQULVKH-UHFFFAOYSA-N n-(5-cyano-3,4-dihydroxy-1-phenylpentan-2-yl)-2-(methanesulfonamido)-1,3-oxazole-4-carboxamide Chemical compound O1C(NS(=O)(=O)C)=NC(C(=O)NC(CC=2C=CC=CC=2)C(O)C(O)CC#N)=C1 JWOVPOURQULVKH-UHFFFAOYSA-N 0.000 claims description 2
- GZFUHVDVTXJCHB-UHFFFAOYSA-N n-(5-cyano-3,4-dihydroxy-1-phenylpentan-2-yl)-2-(methanesulfonamido)-1,3-thiazole-4-carboxamide Chemical compound S1C(NS(=O)(=O)C)=NC(C(=O)NC(CC=2C=CC=CC=2)C(O)C(O)CC#N)=C1 GZFUHVDVTXJCHB-UHFFFAOYSA-N 0.000 claims description 2
- UMAZHHLDJHDQIN-UHFFFAOYSA-N n-(5-cyano-3,4-dihydroxy-1-phenylpentan-2-yl)-2-[methyl(methylsulfonyl)amino]-1,3-thiazole-4-carboxamide Chemical compound S1C(N(C)S(C)(=O)=O)=NC(C(=O)NC(CC=2C=CC=CC=2)C(O)C(O)CC#N)=C1 UMAZHHLDJHDQIN-UHFFFAOYSA-N 0.000 claims description 2
- FMKROJSKFRFBOZ-UHFFFAOYSA-N n-(5-cyano-3,4-dihydroxy-1-pyridin-4-ylpentan-2-yl)-2-(methanesulfonamido)-1,3-oxazole-4-carboxamide Chemical compound O1C(NS(=O)(=O)C)=NC(C(=O)NC(CC=2C=CN=CC=2)C(O)C(O)CC#N)=C1 FMKROJSKFRFBOZ-UHFFFAOYSA-N 0.000 claims description 2
- TWYHXDDYIYVADF-UHFFFAOYSA-N n-(5-cyano-3,4-dihydroxy-1-pyridin-4-ylpentan-2-yl)-2-(methanesulfonamido)-1,3-thiazole-4-carboxamide Chemical compound S1C(NS(=O)(=O)C)=NC(C(=O)NC(CC=2C=CN=CC=2)C(O)C(O)CC#N)=C1 TWYHXDDYIYVADF-UHFFFAOYSA-N 0.000 claims description 2
- BPGNLUYIENRLDZ-UHFFFAOYSA-N n-(5-cyano-3,4-dihydroxy-1-pyridin-4-ylpentan-2-yl)-2-[methyl(methylsulfonyl)amino]-1,3-oxazole-4-carboxamide Chemical compound O1C(N(C)S(C)(=O)=O)=NC(C(=O)NC(CC=2C=CN=CC=2)C(O)C(O)CC#N)=C1 BPGNLUYIENRLDZ-UHFFFAOYSA-N 0.000 claims description 2
- HXDLUPCXCBZOAF-UHFFFAOYSA-N n-(5-cyano-3,4-dihydroxy-1-pyridin-4-ylpentan-2-yl)-2-[methyl(methylsulfonyl)amino]-1,3-thiazole-4-carboxamide Chemical compound S1C(N(C)S(C)(=O)=O)=NC(C(=O)NC(CC=2C=CN=CC=2)C(O)C(O)CC#N)=C1 HXDLUPCXCBZOAF-UHFFFAOYSA-N 0.000 claims description 2
- HKKIFOBUMFFRCB-UHFFFAOYSA-N n-(6-cyano-3,4-dihydroxy-1-phenylhexan-2-yl)-2-(methanesulfonamido)-1,3-oxazole-4-carboxamide Chemical compound O1C(NS(=O)(=O)C)=NC(C(=O)NC(CC=2C=CC=CC=2)C(O)C(O)CCC#N)=C1 HKKIFOBUMFFRCB-UHFFFAOYSA-N 0.000 claims description 2
- MZBTYENZJZQVOV-UHFFFAOYSA-N n-(6-cyano-3,4-dihydroxy-1-phenylhexan-2-yl)-2-(methanesulfonamido)-1,3-thiazole-4-carboxamide Chemical compound S1C(NS(=O)(=O)C)=NC(C(=O)NC(CC=2C=CC=CC=2)C(O)C(O)CCC#N)=C1 MZBTYENZJZQVOV-UHFFFAOYSA-N 0.000 claims description 2
- FKRNHURRWQGMNB-UHFFFAOYSA-N n-(6-cyano-3,4-dihydroxy-1-phenylhexan-2-yl)-2-[methyl(methylsulfonyl)amino]-1,3-thiazole-4-carboxamide Chemical compound S1C(N(C)S(C)(=O)=O)=NC(C(=O)NC(CC=2C=CC=CC=2)C(O)C(O)CCC#N)=C1 FKRNHURRWQGMNB-UHFFFAOYSA-N 0.000 claims description 2
- ANVXHMPIDHJOQF-UHFFFAOYSA-N n-(6-cyano-3,4-dihydroxy-1-pyridin-4-ylhexan-2-yl)-2-(methanesulfonamido)-1,3-oxazole-4-carboxamide Chemical compound O1C(NS(=O)(=O)C)=NC(C(=O)NC(CC=2C=CN=CC=2)C(O)C(O)CCC#N)=C1 ANVXHMPIDHJOQF-UHFFFAOYSA-N 0.000 claims description 2
- BJHDSYBZJBCCNF-UHFFFAOYSA-N n-(6-cyano-3,4-dihydroxy-1-pyridin-4-ylhexan-2-yl)-2-(methanesulfonamido)-1,3-thiazole-4-carboxamide Chemical compound S1C(NS(=O)(=O)C)=NC(C(=O)NC(CC=2C=CN=CC=2)C(O)C(O)CCC#N)=C1 BJHDSYBZJBCCNF-UHFFFAOYSA-N 0.000 claims description 2
- SYTFALXDGMFWHL-UHFFFAOYSA-N n-(6-cyano-3,4-dihydroxy-1-pyridin-4-ylhexan-2-yl)-2-[methyl(methylsulfonyl)amino]-1,3-oxazole-4-carboxamide Chemical compound O1C(N(C)S(C)(=O)=O)=NC(C(=O)NC(CC=2C=CN=CC=2)C(O)C(O)CCC#N)=C1 SYTFALXDGMFWHL-UHFFFAOYSA-N 0.000 claims description 2
- INZYNNPHIUNARM-UHFFFAOYSA-N n-(6-cyano-3,4-dihydroxy-1-pyridin-4-ylhexan-2-yl)-2-[methyl(methylsulfonyl)amino]-1,3-thiazole-4-carboxamide Chemical compound S1C(N(C)S(C)(=O)=O)=NC(C(=O)NC(CC=2C=CN=CC=2)C(O)C(O)CCC#N)=C1 INZYNNPHIUNARM-UHFFFAOYSA-N 0.000 claims description 2
- TWIQPTBIJPNVOP-UHFFFAOYSA-N n-(7-cyano-3,4-dihydroxy-1-phenylheptan-2-yl)-2-(methanesulfonamido)-1,3-oxazole-4-carboxamide Chemical compound O1C(NS(=O)(=O)C)=NC(C(=O)NC(CC=2C=CC=CC=2)C(O)C(O)CCCC#N)=C1 TWIQPTBIJPNVOP-UHFFFAOYSA-N 0.000 claims description 2
- XGDQYIUYQLDHSX-UHFFFAOYSA-N n-(7-cyano-3,4-dihydroxy-1-phenylheptan-2-yl)-2-(methanesulfonamido)-1,3-thiazole-4-carboxamide Chemical compound S1C(NS(=O)(=O)C)=NC(C(=O)NC(CC=2C=CC=CC=2)C(O)C(O)CCCC#N)=C1 XGDQYIUYQLDHSX-UHFFFAOYSA-N 0.000 claims description 2
- ICURTBPAOYSVNI-UHFFFAOYSA-N n-(7-cyano-3,4-dihydroxy-1-phenylheptan-2-yl)-2-[methyl(methylsulfonyl)amino]-1,3-oxazole-4-carboxamide Chemical compound O1C(N(C)S(C)(=O)=O)=NC(C(=O)NC(CC=2C=CC=CC=2)C(O)C(O)CCCC#N)=C1 ICURTBPAOYSVNI-UHFFFAOYSA-N 0.000 claims description 2
- QVUNSCXBESFMFN-UHFFFAOYSA-N n-(7-cyano-3,4-dihydroxy-1-phenylheptan-2-yl)-2-[methyl(methylsulfonyl)amino]-1,3-thiazole-4-carboxamide Chemical compound S1C(N(C)S(C)(=O)=O)=NC(C(=O)NC(CC=2C=CC=CC=2)C(O)C(O)CCCC#N)=C1 QVUNSCXBESFMFN-UHFFFAOYSA-N 0.000 claims description 2
- NIUBBFWMXOGZGE-UHFFFAOYSA-N n-(7-cyano-3,4-dihydroxy-1-pyridin-4-ylheptan-2-yl)-2-(methanesulfonamido)-1,3-oxazole-4-carboxamide Chemical compound O1C(NS(=O)(=O)C)=NC(C(=O)NC(CC=2C=CN=CC=2)C(O)C(O)CCCC#N)=C1 NIUBBFWMXOGZGE-UHFFFAOYSA-N 0.000 claims description 2
- XENVBZCKPVETBG-UHFFFAOYSA-N n-(7-cyano-3,4-dihydroxy-1-pyridin-4-ylheptan-2-yl)-2-(methanesulfonamido)-1,3-thiazole-4-carboxamide Chemical compound S1C(NS(=O)(=O)C)=NC(C(=O)NC(CC=2C=CN=CC=2)C(O)C(O)CCCC#N)=C1 XENVBZCKPVETBG-UHFFFAOYSA-N 0.000 claims description 2
- FWDVOPDUQIPVCK-UHFFFAOYSA-N n-(7-cyano-3,4-dihydroxy-1-pyridin-4-ylheptan-2-yl)-2-[methyl(methylsulfonyl)amino]-1,3-oxazole-4-carboxamide Chemical compound O1C(N(C)S(C)(=O)=O)=NC(C(=O)NC(CC=2C=CN=CC=2)C(O)C(O)CCCC#N)=C1 FWDVOPDUQIPVCK-UHFFFAOYSA-N 0.000 claims description 2
- AVNSVOBGZMKSRF-UHFFFAOYSA-N n-(7-cyano-3,4-dihydroxy-1-pyridin-4-ylheptan-2-yl)-2-[methyl(methylsulfonyl)amino]-1,3-thiazole-4-carboxamide Chemical compound S1C(N(C)S(C)(=O)=O)=NC(C(=O)NC(CC=2C=CN=CC=2)C(O)C(O)CCCC#N)=C1 AVNSVOBGZMKSRF-UHFFFAOYSA-N 0.000 claims description 2
- QNQDJBDWDQDBLD-UHFFFAOYSA-N n-[1-(3,5-difluorophenyl)-3,4-dihydroxynon-8-yn-2-yl]-2-(methanesulfonamido)-1,3-thiazole-4-carboxamide Chemical compound S1C(NS(=O)(=O)C)=NC(C(=O)NC(CC=2C=C(F)C=C(F)C=2)C(O)C(O)CCCC#C)=C1 QNQDJBDWDQDBLD-UHFFFAOYSA-N 0.000 claims description 2
- CALYULJMNQZOMK-UHFFFAOYSA-N n-[1-(3,5-difluorophenyl)-3,4-dihydroxynon-8-yn-2-yl]-2-[methyl(methylsulfonyl)amino]-1,3-thiazole-4-carboxamide Chemical compound S1C(N(C)S(C)(=O)=O)=NC(C(=O)NC(CC=2C=C(F)C=C(F)C=2)C(O)C(O)CCCC#C)=C1 CALYULJMNQZOMK-UHFFFAOYSA-N 0.000 claims description 2
- FXHVXXFIVVWDAT-UHFFFAOYSA-N n-[1-(3,5-difluorophenyl)-3,4-dihydroxynonan-2-yl]-2-(methanesulfonamido)-1,3-oxazole-4-carboxamide Chemical compound C=1OC(NS(C)(=O)=O)=NC=1C(=O)NC(C(O)C(O)CCCCC)CC1=CC(F)=CC(F)=C1 FXHVXXFIVVWDAT-UHFFFAOYSA-N 0.000 claims description 2
- PIRNVDSLNDTNIK-UHFFFAOYSA-N n-[1-(3,5-difluorophenyl)-3,4-dihydroxynonan-2-yl]-2-(methanesulfonamido)-1,3-thiazole-4-carboxamide Chemical compound C=1SC(NS(C)(=O)=O)=NC=1C(=O)NC(C(O)C(O)CCCCC)CC1=CC(F)=CC(F)=C1 PIRNVDSLNDTNIK-UHFFFAOYSA-N 0.000 claims description 2
- XUZGKHJXZKERHR-UHFFFAOYSA-N n-[1-(3,5-difluorophenyl)-3,4-dihydroxynonan-2-yl]-2-[methyl(methylsulfonyl)amino]-1,3-oxazole-4-carboxamide Chemical compound C=1OC(N(C)S(C)(=O)=O)=NC=1C(=O)NC(C(O)C(O)CCCCC)CC1=CC(F)=CC(F)=C1 XUZGKHJXZKERHR-UHFFFAOYSA-N 0.000 claims description 2
- WCJVNUSLKDZRKC-UHFFFAOYSA-N n-[1-(3,5-difluorophenyl)-3,4-dihydroxynonan-2-yl]-2-[methyl(methylsulfonyl)amino]-1,3-thiazole-4-carboxamide Chemical compound C=1SC(N(C)S(C)(=O)=O)=NC=1C(=O)NC(C(O)C(O)CCCCC)CC1=CC(F)=CC(F)=C1 WCJVNUSLKDZRKC-UHFFFAOYSA-N 0.000 claims description 2
- BAUVAAAADBKMGK-UHFFFAOYSA-N n-[1-(3,5-difluorophenyl)-3,4-dihydroxyoctan-2-yl]-2-(methanesulfonamido)-1,3-oxazole-4-carboxamide Chemical compound C=1OC(NS(C)(=O)=O)=NC=1C(=O)NC(C(O)C(O)CCCC)CC1=CC(F)=CC(F)=C1 BAUVAAAADBKMGK-UHFFFAOYSA-N 0.000 claims description 2
- OQDUITWNUREFQL-UHFFFAOYSA-N n-[1-(3,5-difluorophenyl)-3,4-dihydroxyoctan-2-yl]-2-(methanesulfonamido)-1,3-thiazole-4-carboxamide Chemical compound C=1SC(NS(C)(=O)=O)=NC=1C(=O)NC(C(O)C(O)CCCC)CC1=CC(F)=CC(F)=C1 OQDUITWNUREFQL-UHFFFAOYSA-N 0.000 claims description 2
- GVFBRPBVXVMVSW-UHFFFAOYSA-N n-[1-(3,5-difluorophenyl)-3,4-dihydroxyoctan-2-yl]-2-[methyl(methylsulfonyl)amino]-1,3-oxazole-4-carboxamide Chemical compound C=1OC(N(C)S(C)(=O)=O)=NC=1C(=O)NC(C(O)C(O)CCCC)CC1=CC(F)=CC(F)=C1 GVFBRPBVXVMVSW-UHFFFAOYSA-N 0.000 claims description 2
- QKNRBDDPWVSDKC-UHFFFAOYSA-N n-[1-(3,5-difluorophenyl)-3,4-dihydroxyoctan-2-yl]-2-[methyl(methylsulfonyl)amino]-1,3-thiazole-4-carboxamide Chemical compound C=1SC(N(C)S(C)(=O)=O)=NC=1C(=O)NC(C(O)C(O)CCCC)CC1=CC(F)=CC(F)=C1 QKNRBDDPWVSDKC-UHFFFAOYSA-N 0.000 claims description 2
- GGEKMIOXKSDROE-UHFFFAOYSA-N n-[3,4-dihydroxy-1-(4-hydroxyphenyl)non-8-yn-2-yl]-2-(methanesulfonamido)-1,3-thiazole-4-carboxamide Chemical compound S1C(NS(=O)(=O)C)=NC(C(=O)NC(CC=2C=CC(O)=CC=2)C(O)C(O)CCCC#C)=C1 GGEKMIOXKSDROE-UHFFFAOYSA-N 0.000 claims description 2
- MBNBYAPCXZJFPP-UHFFFAOYSA-N n-[3,4-dihydroxy-1-(4-hydroxyphenyl)non-8-yn-2-yl]-2-[methyl(methylsulfonyl)amino]-1,3-oxazole-4-carboxamide Chemical compound O1C(N(C)S(C)(=O)=O)=NC(C(=O)NC(CC=2C=CC(O)=CC=2)C(O)C(O)CCCC#C)=C1 MBNBYAPCXZJFPP-UHFFFAOYSA-N 0.000 claims description 2
- LXNDRCSUOWYNJL-UHFFFAOYSA-N n-[3,4-dihydroxy-1-(4-hydroxyphenyl)non-8-yn-2-yl]-2-[methyl(methylsulfonyl)amino]-1,3-thiazole-4-carboxamide Chemical compound S1C(N(C)S(C)(=O)=O)=NC(C(=O)NC(CC=2C=CC(O)=CC=2)C(O)C(O)CCCC#C)=C1 LXNDRCSUOWYNJL-UHFFFAOYSA-N 0.000 claims description 2
- NQOBVBAZUZUUPX-UHFFFAOYSA-N n-[3,4-dihydroxy-1-(4-hydroxyphenyl)nonan-2-yl]-2-(methanesulfonamido)-1,3-oxazole-4-carboxamide Chemical compound C=1OC(NS(C)(=O)=O)=NC=1C(=O)NC(C(O)C(O)CCCCC)CC1=CC=C(O)C=C1 NQOBVBAZUZUUPX-UHFFFAOYSA-N 0.000 claims description 2
- CURQIYQIVCECSE-UHFFFAOYSA-N n-[3,4-dihydroxy-1-(4-hydroxyphenyl)nonan-2-yl]-2-(methanesulfonamido)-1,3-thiazole-4-carboxamide Chemical compound C=1SC(NS(C)(=O)=O)=NC=1C(=O)NC(C(O)C(O)CCCCC)CC1=CC=C(O)C=C1 CURQIYQIVCECSE-UHFFFAOYSA-N 0.000 claims description 2
- XQWPFTCGGFDJOW-UHFFFAOYSA-N n-[3,4-dihydroxy-1-(4-hydroxyphenyl)nonan-2-yl]-2-[methyl(methylsulfonyl)amino]-1,3-oxazole-4-carboxamide Chemical compound C=1OC(N(C)S(C)(=O)=O)=NC=1C(=O)NC(C(O)C(O)CCCCC)CC1=CC=C(O)C=C1 XQWPFTCGGFDJOW-UHFFFAOYSA-N 0.000 claims description 2
- NNJUXMWDUBHUGC-UHFFFAOYSA-N n-[3,4-dihydroxy-1-(4-hydroxyphenyl)nonan-2-yl]-2-[methyl(methylsulfonyl)amino]-1,3-thiazole-4-carboxamide Chemical compound C=1SC(N(C)S(C)(=O)=O)=NC=1C(=O)NC(C(O)C(O)CCCCC)CC1=CC=C(O)C=C1 NNJUXMWDUBHUGC-UHFFFAOYSA-N 0.000 claims description 2
- WFJGICCEFVXVPT-UHFFFAOYSA-N n-[3,4-dihydroxy-1-(4-hydroxyphenyl)octan-2-yl]-2-(methanesulfonamido)-1,3-oxazole-4-carboxamide Chemical compound C=1OC(NS(C)(=O)=O)=NC=1C(=O)NC(C(O)C(O)CCCC)CC1=CC=C(O)C=C1 WFJGICCEFVXVPT-UHFFFAOYSA-N 0.000 claims description 2
- ZXKUCFQSYVVJSU-UHFFFAOYSA-N n-[3,4-dihydroxy-1-(4-hydroxyphenyl)octan-2-yl]-2-(methanesulfonamido)-1,3-thiazole-4-carboxamide Chemical compound C=1SC(NS(C)(=O)=O)=NC=1C(=O)NC(C(O)C(O)CCCC)CC1=CC=C(O)C=C1 ZXKUCFQSYVVJSU-UHFFFAOYSA-N 0.000 claims description 2
- XGFKSBZYSHTOLB-UHFFFAOYSA-N n-[3,4-dihydroxy-1-(4-hydroxyphenyl)octan-2-yl]-2-[methyl(methylsulfonyl)amino]-1,3-thiazole-4-carboxamide Chemical compound C=1SC(N(C)S(C)(=O)=O)=NC=1C(=O)NC(C(O)C(O)CCCC)CC1=CC=C(O)C=C1 XGFKSBZYSHTOLB-UHFFFAOYSA-N 0.000 claims description 2
- SONIRVREQFAETJ-UHFFFAOYSA-N n-[5-cyano-1-(3,5-difluorophenyl)-3,4-dihydroxypentan-2-yl]-2-(methanesulfonamido)-1,3-oxazole-4-carboxamide Chemical compound O1C(NS(=O)(=O)C)=NC(C(=O)NC(CC=2C=C(F)C=C(F)C=2)C(O)C(O)CC#N)=C1 SONIRVREQFAETJ-UHFFFAOYSA-N 0.000 claims description 2
- MUDHFAKDKREPDI-UHFFFAOYSA-N n-[5-cyano-1-(3,5-difluorophenyl)-3,4-dihydroxypentan-2-yl]-2-(methanesulfonamido)-1,3-thiazole-4-carboxamide Chemical compound S1C(NS(=O)(=O)C)=NC(C(=O)NC(CC=2C=C(F)C=C(F)C=2)C(O)C(O)CC#N)=C1 MUDHFAKDKREPDI-UHFFFAOYSA-N 0.000 claims description 2
- WVHQOHHLKUNXFI-UHFFFAOYSA-N n-[5-cyano-1-(3,5-difluorophenyl)-3,4-dihydroxypentan-2-yl]-2-[methyl(methylsulfonyl)amino]-1,3-oxazole-4-carboxamide Chemical compound O1C(N(C)S(C)(=O)=O)=NC(C(=O)NC(CC=2C=C(F)C=C(F)C=2)C(O)C(O)CC#N)=C1 WVHQOHHLKUNXFI-UHFFFAOYSA-N 0.000 claims description 2
- NUDMZQOKLWVRKJ-UHFFFAOYSA-N n-[5-cyano-1-(3,5-difluorophenyl)-3,4-dihydroxypentan-2-yl]-2-[methyl(methylsulfonyl)amino]-1,3-thiazole-4-carboxamide Chemical compound S1C(N(C)S(C)(=O)=O)=NC(C(=O)NC(CC=2C=C(F)C=C(F)C=2)C(O)C(O)CC#N)=C1 NUDMZQOKLWVRKJ-UHFFFAOYSA-N 0.000 claims description 2
- KTDKGIVLDJWQCG-UHFFFAOYSA-N n-[5-cyano-3,4-dihydroxy-1-(4-hydroxyphenyl)pentan-2-yl]-2-(methanesulfonamido)-1,3-oxazole-4-carboxamide Chemical compound O1C(NS(=O)(=O)C)=NC(C(=O)NC(CC=2C=CC(O)=CC=2)C(O)C(O)CC#N)=C1 KTDKGIVLDJWQCG-UHFFFAOYSA-N 0.000 claims description 2
- LCTYKIWGDIWZOU-UHFFFAOYSA-N n-[5-cyano-3,4-dihydroxy-1-(4-hydroxyphenyl)pentan-2-yl]-2-(methanesulfonamido)-1,3-thiazole-4-carboxamide Chemical compound S1C(NS(=O)(=O)C)=NC(C(=O)NC(CC=2C=CC(O)=CC=2)C(O)C(O)CC#N)=C1 LCTYKIWGDIWZOU-UHFFFAOYSA-N 0.000 claims description 2
- MLKSAXOKSNIZMC-UHFFFAOYSA-N n-[5-cyano-3,4-dihydroxy-1-(4-hydroxyphenyl)pentan-2-yl]-2-[methyl(methylsulfonyl)amino]-1,3-oxazole-4-carboxamide Chemical compound O1C(N(C)S(C)(=O)=O)=NC(C(=O)NC(CC=2C=CC(O)=CC=2)C(O)C(O)CC#N)=C1 MLKSAXOKSNIZMC-UHFFFAOYSA-N 0.000 claims description 2
- LYRHHCFIXANRLO-UHFFFAOYSA-N n-[5-cyano-3,4-dihydroxy-1-(4-hydroxyphenyl)pentan-2-yl]-2-[methyl(methylsulfonyl)amino]-1,3-thiazole-4-carboxamide Chemical compound S1C(N(C)S(C)(=O)=O)=NC(C(=O)NC(CC=2C=CC(O)=CC=2)C(O)C(O)CC#N)=C1 LYRHHCFIXANRLO-UHFFFAOYSA-N 0.000 claims description 2
- XILOSQSWHCLGBH-UHFFFAOYSA-N n-[6-cyano-1-(3,5-difluorophenyl)-3,4-dihydroxyhexan-2-yl]-2-(methanesulfonamido)-1,3-oxazole-4-carboxamide Chemical compound O1C(NS(=O)(=O)C)=NC(C(=O)NC(CC=2C=C(F)C=C(F)C=2)C(O)C(O)CCC#N)=C1 XILOSQSWHCLGBH-UHFFFAOYSA-N 0.000 claims description 2
- AOZJRFPYFNMRNG-UHFFFAOYSA-N n-[6-cyano-1-(3,5-difluorophenyl)-3,4-dihydroxyhexan-2-yl]-2-(methanesulfonamido)-1,3-thiazole-4-carboxamide Chemical compound S1C(NS(=O)(=O)C)=NC(C(=O)NC(CC=2C=C(F)C=C(F)C=2)C(O)C(O)CCC#N)=C1 AOZJRFPYFNMRNG-UHFFFAOYSA-N 0.000 claims description 2
- JQVFRUWJPTUFPW-UHFFFAOYSA-N n-[6-cyano-1-(3,5-difluorophenyl)-3,4-dihydroxyhexan-2-yl]-2-[methyl(methylsulfonyl)amino]-1,3-oxazole-4-carboxamide Chemical compound O1C(N(C)S(C)(=O)=O)=NC(C(=O)NC(CC=2C=C(F)C=C(F)C=2)C(O)C(O)CCC#N)=C1 JQVFRUWJPTUFPW-UHFFFAOYSA-N 0.000 claims description 2
- UERNBSWKTNJXPG-UHFFFAOYSA-N n-[6-cyano-1-(3,5-difluorophenyl)-3,4-dihydroxyhexan-2-yl]-2-[methyl(methylsulfonyl)amino]-1,3-thiazole-4-carboxamide Chemical compound S1C(N(C)S(C)(=O)=O)=NC(C(=O)NC(CC=2C=C(F)C=C(F)C=2)C(O)C(O)CCC#N)=C1 UERNBSWKTNJXPG-UHFFFAOYSA-N 0.000 claims description 2
- WKFPGGSNRHRNKU-UHFFFAOYSA-N n-[6-cyano-3,4-dihydroxy-1-(4-hydroxyphenyl)hexan-2-yl]-2-(methanesulfonamido)-1,3-oxazole-4-carboxamide Chemical compound O1C(NS(=O)(=O)C)=NC(C(=O)NC(CC=2C=CC(O)=CC=2)C(O)C(O)CCC#N)=C1 WKFPGGSNRHRNKU-UHFFFAOYSA-N 0.000 claims description 2
- NLSKTFDAABSMDF-UHFFFAOYSA-N n-[6-cyano-3,4-dihydroxy-1-(4-hydroxyphenyl)hexan-2-yl]-2-(methanesulfonamido)-1,3-thiazole-4-carboxamide Chemical compound S1C(NS(=O)(=O)C)=NC(C(=O)NC(CC=2C=CC(O)=CC=2)C(O)C(O)CCC#N)=C1 NLSKTFDAABSMDF-UHFFFAOYSA-N 0.000 claims description 2
- IFDSHJSAEGGRQJ-UHFFFAOYSA-N n-[6-cyano-3,4-dihydroxy-1-(4-hydroxyphenyl)hexan-2-yl]-2-[methyl(methylsulfonyl)amino]-1,3-thiazole-4-carboxamide Chemical compound S1C(N(C)S(C)(=O)=O)=NC(C(=O)NC(CC=2C=CC(O)=CC=2)C(O)C(O)CCC#N)=C1 IFDSHJSAEGGRQJ-UHFFFAOYSA-N 0.000 claims description 2
- GMSXKMRRNMYAIY-UHFFFAOYSA-N n-[7-cyano-1-(3,5-difluorophenyl)-3,4-dihydroxyheptan-2-yl]-2-(methanesulfonamido)-1,3-oxazole-4-carboxamide Chemical compound O1C(NS(=O)(=O)C)=NC(C(=O)NC(CC=2C=C(F)C=C(F)C=2)C(O)C(O)CCCC#N)=C1 GMSXKMRRNMYAIY-UHFFFAOYSA-N 0.000 claims description 2
- OJUGVPAZOPYCRW-UHFFFAOYSA-N n-[7-cyano-1-(3,5-difluorophenyl)-3,4-dihydroxyheptan-2-yl]-2-(methanesulfonamido)-1,3-thiazole-4-carboxamide Chemical compound S1C(NS(=O)(=O)C)=NC(C(=O)NC(CC=2C=C(F)C=C(F)C=2)C(O)C(O)CCCC#N)=C1 OJUGVPAZOPYCRW-UHFFFAOYSA-N 0.000 claims description 2
- TUCRQLAFGWOCQS-UHFFFAOYSA-N n-[7-cyano-1-(3,5-difluorophenyl)-3,4-dihydroxyheptan-2-yl]-2-[methyl(methylsulfonyl)amino]-1,3-oxazole-4-carboxamide Chemical compound O1C(N(C)S(C)(=O)=O)=NC(C(=O)NC(CC=2C=C(F)C=C(F)C=2)C(O)C(O)CCCC#N)=C1 TUCRQLAFGWOCQS-UHFFFAOYSA-N 0.000 claims description 2
- SDONLCVRJCSXGP-UHFFFAOYSA-N n-[7-cyano-1-(3,5-difluorophenyl)-3,4-dihydroxyheptan-2-yl]-2-[methyl(methylsulfonyl)amino]-1,3-thiazole-4-carboxamide Chemical compound S1C(N(C)S(C)(=O)=O)=NC(C(=O)NC(CC=2C=C(F)C=C(F)C=2)C(O)C(O)CCCC#N)=C1 SDONLCVRJCSXGP-UHFFFAOYSA-N 0.000 claims description 2
- SCEVGOBWCWLWRK-UHFFFAOYSA-N n-[7-cyano-3,4-dihydroxy-1-(4-hydroxyphenyl)heptan-2-yl]-2-(methanesulfonamido)-1,3-oxazole-4-carboxamide Chemical compound O1C(NS(=O)(=O)C)=NC(C(=O)NC(CC=2C=CC(O)=CC=2)C(O)C(O)CCCC#N)=C1 SCEVGOBWCWLWRK-UHFFFAOYSA-N 0.000 claims description 2
- PZYJRNITEREJRR-UHFFFAOYSA-N n-[7-cyano-3,4-dihydroxy-1-(4-hydroxyphenyl)heptan-2-yl]-2-(methanesulfonamido)-1,3-thiazole-4-carboxamide Chemical compound S1C(NS(=O)(=O)C)=NC(C(=O)NC(CC=2C=CC(O)=CC=2)C(O)C(O)CCCC#N)=C1 PZYJRNITEREJRR-UHFFFAOYSA-N 0.000 claims description 2
- HERKZXKEXMMTOB-UHFFFAOYSA-N n-[7-cyano-3,4-dihydroxy-1-(4-hydroxyphenyl)heptan-2-yl]-2-[methyl(methylsulfonyl)amino]-1,3-thiazole-4-carboxamide Chemical compound S1C(N(C)S(C)(=O)=O)=NC(C(=O)NC(CC=2C=CC(O)=CC=2)C(O)C(O)CCCC#N)=C1 HERKZXKEXMMTOB-UHFFFAOYSA-N 0.000 claims description 2
- 125000005309 thioalkoxy group Chemical group 0.000 claims description 2
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 claims 14
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 claims 13
- 125000005865 C2-C10alkynyl group Chemical group 0.000 claims 9
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 6
- 125000004767 (C1-C4) haloalkoxy group Chemical group 0.000 claims 2
- QZOAUGPTYFVWII-UHFFFAOYSA-N 1-n-(3,4-dihydroxy-1-phenylnon-8-yn-2-yl)-3-n,3-n-dipropylbenzene-1,3,5-tricarboxamide Chemical compound CCCN(CCC)C(=O)C1=CC(C(N)=O)=CC(C(=O)NC(CC=2C=CC=CC=2)C(O)C(O)CCCC#C)=C1 QZOAUGPTYFVWII-UHFFFAOYSA-N 0.000 claims 1
- HCHXYKMGADRMPF-UHFFFAOYSA-N 1-n-(5-cyano-3,4-dihydroxy-1-phenylpentan-2-yl)-5-methyl-3-n,3-n-dipropylbenzene-1,3-dicarboxamide Chemical compound CCCN(CCC)C(=O)C1=CC(C)=CC(C(=O)NC(CC=2C=CC=CC=2)C(O)C(O)CC#N)=C1 HCHXYKMGADRMPF-UHFFFAOYSA-N 0.000 claims 1
- ZEMJDTIQTPZYEO-UHFFFAOYSA-N 1-n-(5-cyano-3,4-dihydroxy-1-pyridin-4-ylpentan-2-yl)-3-n,3-n-dipropylbenzene-1,3,5-tricarboxamide Chemical compound CCCN(CCC)C(=O)C1=CC(C(N)=O)=CC(C(=O)NC(CC=2C=CN=CC=2)C(O)C(O)CC#N)=C1 ZEMJDTIQTPZYEO-UHFFFAOYSA-N 0.000 claims 1
- NHRMHYLEJHKQIM-UHFFFAOYSA-N 1-n-(6-cyano-3,4-dihydroxy-1-phenylhexan-2-yl)-3-n,3-n-dipropylbenzene-1,3,5-tricarboxamide Chemical compound CCCN(CCC)C(=O)C1=CC(C(N)=O)=CC(C(=O)NC(CC=2C=CC=CC=2)C(O)C(O)CCC#N)=C1 NHRMHYLEJHKQIM-UHFFFAOYSA-N 0.000 claims 1
- BBJLXBATRZBZQC-UHFFFAOYSA-N 1-n-(6-cyano-3,4-dihydroxy-1-pyridin-4-ylhexan-2-yl)-3-n,3-n-dipropylbenzene-1,3,5-tricarboxamide Chemical compound CCCN(CCC)C(=O)C1=CC(C(N)=O)=CC(C(=O)NC(CC=2C=CN=CC=2)C(O)C(O)CCC#N)=C1 BBJLXBATRZBZQC-UHFFFAOYSA-N 0.000 claims 1
- KJLRFWLZDPKQFY-UHFFFAOYSA-N 1-n-(7-cyano-3,4-dihydroxy-1-pyridin-4-ylheptan-2-yl)-3-n,3-n-dipropylbenzene-1,3,5-tricarboxamide Chemical compound CCCN(CCC)C(=O)C1=CC(C(N)=O)=CC(C(=O)NC(CC=2C=CN=CC=2)C(O)C(O)CCCC#N)=C1 KJLRFWLZDPKQFY-UHFFFAOYSA-N 0.000 claims 1
- RWJSXDABPVWKTG-OYUWMTPXSA-N 1-n-[(2s,3r,4r)-1-(3,5-difluorophenyl)-3,4-dihydroxyoctan-2-yl]-5-methyl-3-n,3-n-dipropylbenzene-1,3-dicarboxamide Chemical compound C([C@@H]([C@@H](O)[C@H](O)CCCC)NC(=O)C=1C=C(C=C(C)C=1)C(=O)N(CCC)CCC)C1=CC(F)=CC(F)=C1 RWJSXDABPVWKTG-OYUWMTPXSA-N 0.000 claims 1
- QTTSZUAFBOPWSA-OJDZSJEKSA-N 1-n-[(2s,3r,4r)-3,4-dihydroxy-1,7-diphenylheptan-2-yl]-3-n,3-n-dipropylbenzene-1,3,5-tricarboxamide Chemical compound CCCN(CCC)C(=O)C1=CC(C(N)=O)=CC(C(=O)N[C@@H](CC=2C=CC=CC=2)[C@@H](O)[C@H](O)CCCC=2C=CC=CC=2)=C1 QTTSZUAFBOPWSA-OJDZSJEKSA-N 0.000 claims 1
- MJEXRAZAGPYXSZ-UHFFFAOYSA-N 1-n-[1-(3,5-difluorophenyl)-3,4-dihydroxynonan-2-yl]-3-n,3-n-dipropylbenzene-1,3,5-tricarboxamide Chemical compound C=1C(C(N)=O)=CC(C(=O)N(CCC)CCC)=CC=1C(=O)NC(C(O)C(O)CCCCC)CC1=CC(F)=CC(F)=C1 MJEXRAZAGPYXSZ-UHFFFAOYSA-N 0.000 claims 1
- RWJSXDABPVWKTG-UHFFFAOYSA-N 1-n-[1-(3,5-difluorophenyl)-3,4-dihydroxyoctan-2-yl]-5-methyl-3-n,3-n-dipropylbenzene-1,3-dicarboxamide Chemical compound C=1C(C)=CC(C(=O)N(CCC)CCC)=CC=1C(=O)NC(C(O)C(O)CCCC)CC1=CC(F)=CC(F)=C1 RWJSXDABPVWKTG-UHFFFAOYSA-N 0.000 claims 1
- KTIYLBABYLJJCK-UHFFFAOYSA-N 1-n-[6-cyano-1-(3,5-difluorophenyl)-3,4-dihydroxyhexan-2-yl]-3-n,3-n-dipropylbenzene-1,3,5-tricarboxamide Chemical compound CCCN(CCC)C(=O)C1=CC(C(N)=O)=CC(C(=O)NC(CC=2C=C(F)C=C(F)C=2)C(O)C(O)CCC#N)=C1 KTIYLBABYLJJCK-UHFFFAOYSA-N 0.000 claims 1
- AMXNYPPEONHPIA-UHFFFAOYSA-N 1-n-[6-cyano-1-(3,5-difluorophenyl)-3,4-dihydroxyhexan-2-yl]-5-methyl-3-n,3-n-dipropylbenzene-1,3-dicarboxamide Chemical compound CCCN(CCC)C(=O)C1=CC(C)=CC(C(=O)NC(CC=2C=C(F)C=C(F)C=2)C(O)C(O)CCC#N)=C1 AMXNYPPEONHPIA-UHFFFAOYSA-N 0.000 claims 1
- ORPTXFLUTXOWIK-UHFFFAOYSA-N 1-n-[7-cyano-1-(3,5-difluorophenyl)-3,4-dihydroxyheptan-2-yl]-3-n,3-n-dipropylbenzene-1,3,5-tricarboxamide Chemical compound CCCN(CCC)C(=O)C1=CC(C(N)=O)=CC(C(=O)NC(CC=2C=C(F)C=C(F)C=2)C(O)C(O)CCCC#N)=C1 ORPTXFLUTXOWIK-UHFFFAOYSA-N 0.000 claims 1
- ZGZFNFGFCZBSHB-UHFFFAOYSA-N N-(6-cyano-3,4-dihydroxy-1-phenylhexan-2-yl)-2-[methyl(methylsulfonyl)amino]-1,3-oxazole-4-carboxamide N-(5-cyano-3,4-dihydroxy-1-phenylpentan-2-yl)-2-[methyl(methylsulfonyl)amino]-1,3-oxazole-4-carboxamide Chemical compound C(C1=CC=CC=C1)C(C(C(CC#N)O)O)NC(=O)C=1N=C(OC1)N(S(=O)(=O)C)C.C(C1=CC=CC=C1)C(C(C(CCC#N)O)O)NC(=O)C=1N=C(OC1)N(S(=O)(=O)C)C ZGZFNFGFCZBSHB-UHFFFAOYSA-N 0.000 claims 1
- 150000003857 carboxamides Chemical class 0.000 claims 1
- YOGZLGLNOIHONC-UHFFFAOYSA-N n-(3,4-dihydroxy-1-phenylnonan-2-yl)-2-[methyl(methylsulfonyl)amino]-1,3-thiazole-4-carboxamide Chemical compound C=1SC(N(C)S(C)(=O)=O)=NC=1C(=O)NC(C(O)C(O)CCCCC)CC1=CC=CC=C1 YOGZLGLNOIHONC-UHFFFAOYSA-N 0.000 claims 1
- JYQGIWIBLFOEBW-UHFFFAOYSA-N n-(3,4-dihydroxy-1-pyridin-4-ylnonan-2-yl)-2-(methanesulfonamido)-1,3-thiazole-4-carboxamide Chemical compound C=1SC(NS(C)(=O)=O)=NC=1C(=O)NC(C(O)C(O)CCCCC)CC1=CC=NC=C1 JYQGIWIBLFOEBW-UHFFFAOYSA-N 0.000 claims 1
- XRPHPHSELWRRSQ-UHFFFAOYSA-N n-[1-(3,5-difluorophenyl)-3,4-dihydroxynon-8-yn-2-yl]-2-(methanesulfonamido)-1,3-oxazole-4-carboxamide Chemical compound O1C(NS(=O)(=O)C)=NC(C(=O)NC(CC=2C=C(F)C=C(F)C=2)C(O)C(O)CCCC#C)=C1 XRPHPHSELWRRSQ-UHFFFAOYSA-N 0.000 claims 1
- PWJWNFFKDWDGBE-UHFFFAOYSA-N n-[3,4-dihydroxy-1-(4-hydroxyphenyl)non-8-yn-2-yl]-2-(methanesulfonamido)-1,3-oxazole-4-carboxamide Chemical compound O1C(NS(=O)(=O)C)=NC(C(=O)NC(CC=2C=CC(O)=CC=2)C(O)C(O)CCCC#C)=C1 PWJWNFFKDWDGBE-UHFFFAOYSA-N 0.000 claims 1
- NAEYFZJGFWGELC-UHFFFAOYSA-N n-[3,4-dihydroxy-1-(4-hydroxyphenyl)octan-2-yl]-2-[methyl(methylsulfonyl)amino]-1,3-oxazole-4-carboxamide Chemical compound C=1OC(N(C)S(C)(=O)=O)=NC=1C(=O)NC(C(O)C(O)CCCC)CC1=CC=C(O)C=C1 NAEYFZJGFWGELC-UHFFFAOYSA-N 0.000 claims 1
- 108010043324 Amyloid Precursor Protein Secretases Proteins 0.000 abstract description 103
- 102000002659 Amyloid Precursor Protein Secretases Human genes 0.000 abstract description 103
- 239000003112 inhibitor Substances 0.000 abstract description 51
- 108090000765 processed proteins & peptides Proteins 0.000 abstract description 41
- 230000015572 biosynthetic process Effects 0.000 abstract description 16
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 7
- 230000008021 deposition Effects 0.000 abstract description 3
- 241000124008 Mammalia Species 0.000 abstract description 2
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 description 100
- 101710137189 Amyloid-beta A4 protein Proteins 0.000 description 93
- 102100022704 Amyloid-beta precursor protein Human genes 0.000 description 93
- 101710151993 Amyloid-beta precursor protein Proteins 0.000 description 93
- 239000000203 mixture Substances 0.000 description 74
- 238000003776 cleavage reaction Methods 0.000 description 72
- 230000007017 scission Effects 0.000 description 72
- 239000000758 substrate Substances 0.000 description 49
- 230000000694 effects Effects 0.000 description 42
- 238000003556 assay Methods 0.000 description 40
- 230000002401 inhibitory effect Effects 0.000 description 38
- 125000003342 alkenyl group Chemical group 0.000 description 35
- 102000004190 Enzymes Human genes 0.000 description 32
- 108090000790 Enzymes Proteins 0.000 description 32
- 229940088598 enzyme Drugs 0.000 description 32
- 102100033350 ATP-dependent translocase ABCB1 Human genes 0.000 description 29
- 210000004027 cell Anatomy 0.000 description 29
- 101001017818 Homo sapiens ATP-dependent translocase ABCB1 Proteins 0.000 description 28
- 239000000243 solution Substances 0.000 description 26
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical group N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 24
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 24
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 24
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 22
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 22
- 210000004556 brain Anatomy 0.000 description 22
- 239000002552 dosage form Substances 0.000 description 22
- 230000005764 inhibitory process Effects 0.000 description 22
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 21
- 241001465754 Metazoa Species 0.000 description 20
- 239000000047 product Substances 0.000 description 20
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 18
- 208000037259 Amyloid Plaque Diseases 0.000 description 16
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- 230000035772 mutation Effects 0.000 description 15
- 239000011541 reaction mixture Substances 0.000 description 15
- 238000003786 synthesis reaction Methods 0.000 description 15
- 239000012267 brine Substances 0.000 description 14
- 238000011534 incubation Methods 0.000 description 14
- 125000006239 protecting group Chemical group 0.000 description 14
- 230000002829 reductive effect Effects 0.000 description 14
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 14
- 229940024606 amino acid Drugs 0.000 description 13
- 150000001413 amino acids Chemical class 0.000 description 13
- 238000012360 testing method Methods 0.000 description 13
- 235000001014 amino acid Nutrition 0.000 description 12
- 229960002685 biotin Drugs 0.000 description 12
- 235000020958 biotin Nutrition 0.000 description 12
- 239000011616 biotin Substances 0.000 description 12
- 238000006243 chemical reaction Methods 0.000 description 12
- 239000000543 intermediate Substances 0.000 description 12
- 229920006395 saturated elastomer Polymers 0.000 description 12
- VGIRNWJSIRVFRT-UHFFFAOYSA-N 2',7'-difluorofluorescein Chemical compound OC(=O)C1=CC=CC=C1C1=C2C=C(F)C(=O)C=C2OC2=CC(O)=C(F)C=C21 VGIRNWJSIRVFRT-UHFFFAOYSA-N 0.000 description 11
- 239000002775 capsule Substances 0.000 description 11
- 238000001514 detection method Methods 0.000 description 11
- 238000009472 formulation Methods 0.000 description 11
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 11
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 11
- 230000002255 enzymatic effect Effects 0.000 description 10
- 235000019439 ethyl acetate Nutrition 0.000 description 10
- 238000003018 immunoassay Methods 0.000 description 10
- 230000001404 mediated effect Effects 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 102100021257 Beta-secretase 1 Human genes 0.000 description 9
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 9
- 210000005013 brain tissue Anatomy 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 9
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 9
- 239000012044 organic layer Substances 0.000 description 9
- 230000008569 process Effects 0.000 description 9
- 239000000725 suspension Substances 0.000 description 9
- 230000001225 therapeutic effect Effects 0.000 description 9
- 241000282412 Homo Species 0.000 description 8
- 230000000875 corresponding effect Effects 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 238000012545 processing Methods 0.000 description 8
- 208000024891 symptom Diseases 0.000 description 8
- 239000003826 tablet Substances 0.000 description 8
- 238000002965 ELISA Methods 0.000 description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 7
- OHKFXGKHSJKKAL-NRPADANISA-N Ser-Glu-Val Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(O)=O OHKFXGKHSJKKAL-NRPADANISA-N 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 7
- 125000003282 alkyl amino group Chemical group 0.000 description 7
- 238000010171 animal model Methods 0.000 description 7
- 230000002490 cerebral effect Effects 0.000 description 7
- 239000003937 drug carrier Substances 0.000 description 7
- 239000012634 fragment Substances 0.000 description 7
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 7
- 102000004196 processed proteins & peptides Human genes 0.000 description 7
- 239000003039 volatile agent Substances 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- FBHOPGDGELNWRH-DRZSPHRISA-N Ala-Glu-Phe Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O FBHOPGDGELNWRH-DRZSPHRISA-N 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- 230000002378 acidificating effect Effects 0.000 description 6
- 150000001412 amines Chemical class 0.000 description 6
- 239000000969 carrier Substances 0.000 description 6
- 239000003085 diluting agent Substances 0.000 description 6
- 239000007943 implant Substances 0.000 description 6
- 229910052740 iodine Inorganic materials 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- 210000002784 stomach Anatomy 0.000 description 6
- 125000001424 substituent group Chemical group 0.000 description 6
- 125000006288 3,5-difluorobenzyl group Chemical group [H]C1=C(F)C([H])=C(C([H])=C1F)C([H])([H])* 0.000 description 5
- BXUHCIXDSWRSBS-CIUDSAMLSA-N Asn-Leu-Asp Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(O)=O BXUHCIXDSWRSBS-CIUDSAMLSA-N 0.000 description 5
- AUTNXSQEVVHSJK-YVNDNENWSA-N Glu-Glu-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CCC(O)=O AUTNXSQEVVHSJK-YVNDNENWSA-N 0.000 description 5
- 208000032843 Hemorrhage Diseases 0.000 description 5
- 101000894895 Homo sapiens Beta-secretase 1 Proteins 0.000 description 5
- CKRFDMPBSWYOBT-PPCPHDFISA-N Ile-Lys-Thr Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)O)N CKRFDMPBSWYOBT-PPCPHDFISA-N 0.000 description 5
- 101710175625 Maltose/maltodextrin-binding periplasmic protein Proteins 0.000 description 5
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 5
- 230000009471 action Effects 0.000 description 5
- 239000011149 active material Substances 0.000 description 5
- 239000006071 cream Substances 0.000 description 5
- 208000035475 disorder Diseases 0.000 description 5
- VFRSADQPWYCXDG-LEUCUCNGSA-N ethyl (2s,5s)-5-methylpyrrolidine-2-carboxylate;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.CCOC(=O)[C@@H]1CC[C@H](C)N1 VFRSADQPWYCXDG-LEUCUCNGSA-N 0.000 description 5
- 239000012530 fluid Substances 0.000 description 5
- 102000037865 fusion proteins Human genes 0.000 description 5
- 108020001507 fusion proteins Proteins 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 230000000306 recurrent effect Effects 0.000 description 5
- 230000009261 transgenic effect Effects 0.000 description 5
- 239000003981 vehicle Substances 0.000 description 5
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 4
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 4
- PBAMJJXWDQXOJA-FXQIFTODSA-N Ala-Asp-Arg Chemical compound C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CCCN=C(N)N PBAMJJXWDQXOJA-FXQIFTODSA-N 0.000 description 4
- SVHRPCMZTWZROG-DCAQKATOSA-N Arg-Cys-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)[C@H](CS)NC(=O)[C@H](CCCN=C(N)N)N SVHRPCMZTWZROG-DCAQKATOSA-N 0.000 description 4
- 101710150192 Beta-secretase 1 Proteins 0.000 description 4
- UOACKFBJUYNSLK-XRKIENNPSA-N Estradiol Cypionate Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H](C4=CC=C(O)C=C4CC3)CC[C@@]21C)C(=O)CCC1CCCC1 UOACKFBJUYNSLK-XRKIENNPSA-N 0.000 description 4
- LHYJCVCQPWRMKZ-WEDXCCLWSA-N Gly-Leu-Thr Chemical compound [H]NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O LHYJCVCQPWRMKZ-WEDXCCLWSA-N 0.000 description 4
- SOEGEPHNZOISMT-BYPYZUCNSA-N Gly-Ser-Gly Chemical compound NCC(=O)N[C@@H](CO)C(=O)NCC(O)=O SOEGEPHNZOISMT-BYPYZUCNSA-N 0.000 description 4
- AEDWWMMHUGYIFD-HJGDQZAQSA-N Leu-Thr-Asn Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(O)=O AEDWWMMHUGYIFD-HJGDQZAQSA-N 0.000 description 4
- 102000001708 Protein Isoforms Human genes 0.000 description 4
- 108010029485 Protein Isoforms Proteins 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- GZYNMZQXFRWDFH-YTWAJWBKSA-N Thr-Arg-Pro Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@@H]1C(=O)O)N)O GZYNMZQXFRWDFH-YTWAJWBKSA-N 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 239000003963 antioxidant agent Substances 0.000 description 4
- 235000006708 antioxidants Nutrition 0.000 description 4
- 239000011230 binding agent Substances 0.000 description 4
- 229910052794 bromium Inorganic materials 0.000 description 4
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 4
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 4
- 239000000460 chlorine Substances 0.000 description 4
- 229910052801 chlorine Inorganic materials 0.000 description 4
- 230000001149 cognitive effect Effects 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- 238000003818 flash chromatography Methods 0.000 description 4
- 229910052731 fluorine Inorganic materials 0.000 description 4
- 230000004927 fusion Effects 0.000 description 4
- 108010050848 glycylleucine Proteins 0.000 description 4
- 150000002431 hydrogen Chemical class 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 108010054155 lysyllysine Proteins 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 210000002569 neuron Anatomy 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- 239000002674 ointment Substances 0.000 description 4
- 239000006186 oral dosage form Substances 0.000 description 4
- 239000007909 solid dosage form Substances 0.000 description 4
- 239000012730 sustained-release form Substances 0.000 description 4
- 229940124597 therapeutic agent Drugs 0.000 description 4
- DGPBCNPBWYHUAL-MELADBBJSA-N (2s,3r,4s)-2-amino-1-(3,5-difluorophenyl)octane-3,4-diol Chemical compound CCCC[C@H](O)[C@H](O)[C@@H](N)CC1=CC(F)=CC(F)=C1 DGPBCNPBWYHUAL-MELADBBJSA-N 0.000 description 3
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 3
- UCCVUNQWERTTPW-UHFFFAOYSA-N 3-(dipropylcarbamoyl)-5-methylbenzoic acid Chemical compound CCCN(CCC)C(=O)C1=CC(C)=CC(C(O)=O)=C1 UCCVUNQWERTTPW-UHFFFAOYSA-N 0.000 description 3
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 101800001718 Amyloid-beta protein Proteins 0.000 description 3
- 206010059245 Angiopathy Diseases 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- QMMFVYPAHWMCMS-UHFFFAOYSA-N Dimethyl sulfide Chemical compound CSC QMMFVYPAHWMCMS-UHFFFAOYSA-N 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 108010090804 Streptavidin Proteins 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 150000001299 aldehydes Chemical class 0.000 description 3
- 150000001336 alkenes Chemical class 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 3
- 230000036765 blood level Effects 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 210000004899 c-terminal region Anatomy 0.000 description 3
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 3
- 238000000423 cell based assay Methods 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 230000003920 cognitive function Effects 0.000 description 3
- 238000010511 deprotection reaction Methods 0.000 description 3
- 125000004914 dipropylamino group Chemical group C(CC)N(CCC)* 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000006911 enzymatic reaction Methods 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 210000002682 neurofibrillary tangle Anatomy 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 description 3
- 239000001301 oxygen Chemical group 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- 239000006201 parenteral dosage form Substances 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 125000004076 pyridyl group Chemical group 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 238000013268 sustained release Methods 0.000 description 3
- 229960001685 tacrine Drugs 0.000 description 3
- YLJREFDVOIBQDA-UHFFFAOYSA-N tacrine Chemical compound C1=CC=C2C(N)=C(CCCC3)C3=NC2=C1 YLJREFDVOIBQDA-UHFFFAOYSA-N 0.000 description 3
- ZJTYRNPLVNMVPQ-LBPRGKRZSA-N tert-butyl n-[(2s)-1-oxo-3-phenylpropan-2-yl]carbamate Chemical compound CC(C)(C)OC(=O)N[C@H](C=O)CC1=CC=CC=C1 ZJTYRNPLVNMVPQ-LBPRGKRZSA-N 0.000 description 3
- XNBJSXVDXAMFOI-GVDBMIGSSA-N tert-butyl n-[(2s,3r,4r)-1-(3,5-difluorophenyl)-3,4-dihydroxyoctan-2-yl]carbamate Chemical compound CCCC[C@@H](O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)CC1=CC(F)=CC(F)=C1 XNBJSXVDXAMFOI-GVDBMIGSSA-N 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- XTZVROBFUSNGEZ-NPTJMSEESA-N (2s,3r,4s)-2-amino-1-phenyloctane-3,4-diol;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.CCCC[C@H](O)[C@H](O)[C@@H](N)CC1=CC=CC=C1 XTZVROBFUSNGEZ-NPTJMSEESA-N 0.000 description 2
- 125000006528 (C2-C6) alkyl group Chemical group 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 2
- PVYFYYQOZUBFTL-UHFFFAOYSA-N 3-bromo-5-(dipropylcarbamoyl)benzoic acid Chemical compound CCCN(CCC)C(=O)C1=CC(Br)=CC(C(O)=O)=C1 PVYFYYQOZUBFTL-UHFFFAOYSA-N 0.000 description 2
- SXLDRLWDQNBPOJ-UHFFFAOYSA-N 3-carbamoyl-5-(dipropylcarbamoyl)benzoic acid Chemical compound CCCN(CCC)C(=O)C1=CC(C(N)=O)=CC(C(O)=O)=C1 SXLDRLWDQNBPOJ-UHFFFAOYSA-N 0.000 description 2
- 229940100578 Acetylcholinesterase inhibitor Drugs 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 108010017640 Aspartic Acid Proteases Proteins 0.000 description 2
- 102000004580 Aspartic Acid Proteases Human genes 0.000 description 2
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 2
- 239000004215 Carbon black (E152) Substances 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- DZLQXIFVQFTFJY-BYPYZUCNSA-N Cys-Gly-Gly Chemical compound SC[C@H](N)C(=O)NCC(=O)NCC(O)=O DZLQXIFVQFTFJY-BYPYZUCNSA-N 0.000 description 2
- 208000031124 Dementia Alzheimer type Diseases 0.000 description 2
- 206010061818 Disease progression Diseases 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 239000007821 HATU Substances 0.000 description 2
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 2
- 229910010084 LiAlH4 Inorganic materials 0.000 description 2
- 241000699660 Mus musculus Species 0.000 description 2
- 108010079364 N-glycylalanine Proteins 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- XSVMFMHYUFZWBK-NSHDSACASA-N Rivastigmine Chemical compound CCN(C)C(=O)OC1=CC=CC([C@H](C)N(C)C)=C1 XSVMFMHYUFZWBK-NSHDSACASA-N 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- 239000006180 TBST buffer Substances 0.000 description 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 230000006933 amyloid-beta aggregation Effects 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 2
- 125000004600 benzothiopyranyl group Chemical group S1C(C=CC2=C1C=CC=C2)* 0.000 description 2
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- 239000000090 biomarker Substances 0.000 description 2
- 235000011089 carbon dioxide Nutrition 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 230000019771 cognition Effects 0.000 description 2
- 238000013270 controlled release Methods 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 125000004093 cyano group Chemical group *C#N 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- 150000002009 diols Chemical class 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 230000005750 disease progression Effects 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- XWAIAVWHZJNZQQ-UHFFFAOYSA-N donepezil hydrochloride Chemical compound [H+].[Cl-].O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 XWAIAVWHZJNZQQ-UHFFFAOYSA-N 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 239000002662 enteric coated tablet Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 238000002875 fluorescence polarization Methods 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000003540 gamma secretase inhibitor Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- VPZXBVLAVMBEQI-UHFFFAOYSA-N glycyl-DL-alpha-alanine Natural products OC(=O)C(C)NC(=O)CN VPZXBVLAVMBEQI-UHFFFAOYSA-N 0.000 description 2
- 230000000971 hippocampal effect Effects 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 125000004857 imidazopyridinyl group Chemical group N1C(=NC2=C1C=CC=N2)* 0.000 description 2
- 239000003701 inert diluent Substances 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000007913 intrathecal administration Methods 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 239000008297 liquid dosage form Substances 0.000 description 2
- 239000012280 lithium aluminium hydride Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- RMGJCSHZTFKPNO-UHFFFAOYSA-M magnesium;ethene;bromide Chemical compound [Mg+2].[Br-].[CH-]=C RMGJCSHZTFKPNO-UHFFFAOYSA-M 0.000 description 2
- 230000006386 memory function Effects 0.000 description 2
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 2
- 229940097496 nasal spray Drugs 0.000 description 2
- 239000007922 nasal spray Substances 0.000 description 2
- 208000015122 neurodegenerative disease Diseases 0.000 description 2
- 239000003076 neurotropic agent Substances 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 229910000489 osmium tetroxide Inorganic materials 0.000 description 2
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 2
- 125000001484 phenothiazinyl group Chemical class C1(=CC=CC=2SC3=CC=CC=C3NC12)* 0.000 description 2
- 235000021317 phosphate Nutrition 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- IVDFJHOHABJVEH-UHFFFAOYSA-N pinacol Chemical compound CC(C)(O)C(C)(C)O IVDFJHOHABJVEH-UHFFFAOYSA-N 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- LOUPRKONTZGTKE-LHHVKLHASA-N quinidine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@H]2[C@@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-LHHVKLHASA-N 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000007892 solid unit dosage form Substances 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000011593 sulfur Chemical group 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- GHLHRXCJZZQVFC-LBPRGKRZSA-N tert-butyl n-[(2s)-1-(3,5-difluorophenyl)-3-oxopropan-2-yl]carbamate Chemical compound CC(C)(C)OC(=O)N[C@H](C=O)CC1=CC(F)=CC(F)=C1 GHLHRXCJZZQVFC-LBPRGKRZSA-N 0.000 description 2
- XNBJSXVDXAMFOI-YESZJQIVSA-N tert-butyl n-[(2s,3r,4s)-1-(3,5-difluorophenyl)-3,4-dihydroxyoctan-2-yl]carbamate Chemical compound CCCC[C@H](O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)CC1=CC(F)=CC(F)=C1 XNBJSXVDXAMFOI-YESZJQIVSA-N 0.000 description 2
- 125000005958 tetrahydrothienyl group Chemical group 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 238000011820 transgenic animal model Methods 0.000 description 2
- 238000011830 transgenic mouse model Methods 0.000 description 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 2
- YFZCWRCBISUCFG-ZDMORDKWSA-N (2s)-2-[[(2s)-6-amino-2-[[(2s)-1-[(2s,3r)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[2-[[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxybutanoyl]pyrr Chemical compound C([C@@H](C(=O)N[C@@H]([C@H](O)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)CNC(=O)[C@@H](N)CCCN=C(N)N)C1=CC=C(O)C=C1 YFZCWRCBISUCFG-ZDMORDKWSA-N 0.000 description 1
- CZBNUDVCRKSYDG-NSHDSACASA-N (2s)-3-(3,5-difluorophenyl)-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoic acid Chemical compound CC(C)(C)OC(=O)N[C@H](C(O)=O)CC1=CC(F)=CC(F)=C1 CZBNUDVCRKSYDG-NSHDSACASA-N 0.000 description 1
- ZOPARMKBYZRXBN-IPMKNSEASA-N (2s,3r,4r)-2-amino-1,7-diphenylheptane-3,4-diol Chemical compound C([C@H](N)[C@@H](O)[C@H](O)CCCC=1C=CC=CC=1)C1=CC=CC=C1 ZOPARMKBYZRXBN-IPMKNSEASA-N 0.000 description 1
- YLLNSLBILPSYBM-JQPLGUQCSA-N (2s,3r,4r)-2-amino-1,7-diphenylheptane-3,4-diol;2,2,2-trifluoroacetic acid Chemical class OC(=O)C(F)(F)F.C([C@H](N)[C@@H](O)[C@H](O)CCCC=1C=CC=CC=1)C1=CC=CC=C1 YLLNSLBILPSYBM-JQPLGUQCSA-N 0.000 description 1
- DGPBCNPBWYHUAL-BFHYXJOUSA-N (2s,3r,4r)-2-amino-1-(3,5-difluorophenyl)octane-3,4-diol Chemical compound CCCC[C@@H](O)[C@H](O)[C@@H](N)CC1=CC(F)=CC(F)=C1 DGPBCNPBWYHUAL-BFHYXJOUSA-N 0.000 description 1
- DNDAFEILZMWNSS-YNEHKIRRSA-N (2s,3r,4r)-2-amino-6-methylsulfanyl-1-phenylhexane-3,4-diol Chemical compound CSCC[C@@H](O)[C@H](O)[C@@H](N)CC1=CC=CC=C1 DNDAFEILZMWNSS-YNEHKIRRSA-N 0.000 description 1
- UAQKJEDDYKAIKT-NPTJMSEESA-N (2s,3r,4s)-2-amino-1-(3,5-difluorophenyl)octane-3,4-diol;hydrochloride Chemical compound Cl.CCCC[C@H](O)[C@H](O)[C@@H](N)CC1=CC(F)=CC(F)=C1 UAQKJEDDYKAIKT-NPTJMSEESA-N 0.000 description 1
- PVYMUOUGXMQFNA-MELADBBJSA-N (2s,3r,4s)-2-amino-1-phenyloctane-3,4-diol Chemical compound CCCC[C@H](O)[C@H](O)[C@@H](N)CC1=CC=CC=C1 PVYMUOUGXMQFNA-MELADBBJSA-N 0.000 description 1
- DNDAFEILZMWNSS-RWMBFGLXSA-N (2s,3r,4s)-2-amino-6-methylsulfanyl-1-phenylhexane-3,4-diol Chemical compound CSCC[C@H](O)[C@H](O)[C@@H](N)CC1=CC=CC=C1 DNDAFEILZMWNSS-RWMBFGLXSA-N 0.000 description 1
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 description 1
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
- VDMKJSJJXQDICL-ZXVJYWQYSA-N 1,7-dipyridin-3-ylheptan-4-yl (2s)-1-[2-oxo-2-(3,4,5-trimethoxyphenyl)acetyl]piperidine-2-carboxylate;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.OC(=O)CC(O)(C(O)=O)CC(O)=O.COC1=C(OC)C(OC)=CC(C(=O)C(=O)N2[C@@H](CCCC2)C(=O)OC(CCCC=2C=NC=CC=2)CCCC=2C=NC=CC=2)=C1 VDMKJSJJXQDICL-ZXVJYWQYSA-N 0.000 description 1
- PDVXUMMVAWACHL-UHFFFAOYSA-N 1-n-(6-cyano-3,4-dihydroxy-1-pyridin-4-ylhexan-2-yl)-5-methyl-3-n,3-n-dipropylbenzene-1,3-dicarboxamide Chemical compound CCCN(CCC)C(=O)C1=CC(C)=CC(C(=O)NC(CC=2C=CN=CC=2)C(O)C(O)CCC#N)=C1 PDVXUMMVAWACHL-UHFFFAOYSA-N 0.000 description 1
- HQKUCXIEUGIPCA-UHFFFAOYSA-N 1-n-(7-cyano-3,4-dihydroxy-1-phenylheptan-2-yl)-3-n,3-n-dipropylbenzene-1,3,5-tricarboxamide Chemical compound CCCN(CCC)C(=O)C1=CC(C(N)=O)=CC(C(=O)NC(CC=2C=CC=CC=2)C(O)C(O)CCCC#N)=C1 HQKUCXIEUGIPCA-UHFFFAOYSA-N 0.000 description 1
- WMDGYQCKMSZYOG-HZFUHODCSA-N 1-n-[(2s,3r,4s)-1-(3,5-difluorophenyl)-3,4-dihydroxynonan-2-yl]-5-methyl-3-n,3-n-dipropylbenzene-1,3-dicarboxamide Chemical compound C([C@@H]([C@@H](O)[C@@H](O)CCCCC)NC(=O)C=1C=C(C=C(C)C=1)C(=O)N(CCC)CCC)C1=CC(F)=CC(F)=C1 WMDGYQCKMSZYOG-HZFUHODCSA-N 0.000 description 1
- ALCHLYSYYJLTFT-HZFUHODCSA-N 1-n-[(2s,3r,4s)-3,4-dihydroxy-1-phenylnonan-2-yl]-5-methyl-3-n,3-n-dipropylbenzene-1,3-dicarboxamide Chemical compound C([C@@H]([C@@H](O)[C@@H](O)CCCCC)NC(=O)C=1C=C(C=C(C)C=1)C(=O)N(CCC)CCC)C1=CC=CC=C1 ALCHLYSYYJLTFT-HZFUHODCSA-N 0.000 description 1
- ONZNOFBHDSIQOQ-UHFFFAOYSA-N 1-n-[7-cyano-3,4-dihydroxy-1-(4-hydroxyphenyl)heptan-2-yl]-3-n,3-n-dipropylbenzene-1,3,5-tricarboxamide Chemical compound CCCN(CCC)C(=O)C1=CC(C(N)=O)=CC(C(=O)NC(CC=2C=CC(O)=CC=2)C(O)C(O)CCCC#N)=C1 ONZNOFBHDSIQOQ-UHFFFAOYSA-N 0.000 description 1
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 description 1
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 1
- UTQNKKSJPHTPBS-UHFFFAOYSA-N 2,2,2-trichloroethanone Chemical group ClC(Cl)(Cl)[C]=O UTQNKKSJPHTPBS-UHFFFAOYSA-N 0.000 description 1
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 1
- 229940058020 2-amino-2-methyl-1-propanol Drugs 0.000 description 1
- OIWXLVBZDMAARO-UHFFFAOYSA-N 2-decylsulfanylethanamine Chemical compound CCCCCCCCCCSCCN OIWXLVBZDMAARO-UHFFFAOYSA-N 0.000 description 1
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- 125000004211 3,5-difluorophenyl group Chemical group [H]C1=C(F)C([H])=C(*)C([H])=C1F 0.000 description 1
- 125000005917 3-methylpentyl group Chemical group 0.000 description 1
- 125000005925 3-methylpentyloxy group Chemical group 0.000 description 1
- CLUWOWRTHNNBBU-UHFFFAOYSA-N 3-methylthiopropanal Chemical compound CSCCC=O CLUWOWRTHNNBBU-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- NHFRGTVSKOPUBK-UHFFFAOYSA-N 4-phenylbutanal Chemical compound O=CCCCC1=CC=CC=C1 NHFRGTVSKOPUBK-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 102000009091 Amyloidogenic Proteins Human genes 0.000 description 1
- 108010048112 Amyloidogenic Proteins Proteins 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 230000007351 Aβ plaque formation Effects 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical class [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 206010008805 Chromosomal abnormalities Diseases 0.000 description 1
- 208000031404 Chromosome Aberrations Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000010907 Cyclooxygenase 2 Human genes 0.000 description 1
- 108010037462 Cyclooxygenase 2 Proteins 0.000 description 1
- 229930105110 Cyclosporin A Natural products 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- GCDLPNRHPWBKJJ-WDSKDSINSA-N Cys-Gly-Glu Chemical compound [H]N[C@@H](CS)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(O)=O GCDLPNRHPWBKJJ-WDSKDSINSA-N 0.000 description 1
- XTHUKRLJRUVVBF-WHFBIAKZSA-N Cys-Gly-Ser Chemical compound SC[C@H](N)C(=O)NCC(=O)N[C@@H](CO)C(O)=O XTHUKRLJRUVVBF-WHFBIAKZSA-N 0.000 description 1
- KGIHMGPYGXBYJJ-SRVKXCTJSA-N Cys-Lys-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CS KGIHMGPYGXBYJJ-SRVKXCTJSA-N 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 229940125373 Gamma-Secretase Inhibitor Drugs 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- IWUFOVSLWADEJC-AVGNSLFASA-N Gln-His-Leu Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(C)C)C(O)=O IWUFOVSLWADEJC-AVGNSLFASA-N 0.000 description 1
- ITYRYNUZHPNCIK-GUBZILKMSA-N Glu-Ala-Leu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(O)=O ITYRYNUZHPNCIK-GUBZILKMSA-N 0.000 description 1
- IUZGUFAJDBHQQV-YUMQZZPRSA-N Gly-Leu-Asn Chemical compound NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O IUZGUFAJDBHQQV-YUMQZZPRSA-N 0.000 description 1
- 239000007818 Grignard reagent Substances 0.000 description 1
- TWROVBNEHJSXDG-IHRRRGAJSA-N His-Leu-Val Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(O)=O TWROVBNEHJSXDG-IHRRRGAJSA-N 0.000 description 1
- 101000823051 Homo sapiens Amyloid-beta precursor protein Proteins 0.000 description 1
- 101001033280 Homo sapiens Cytokine receptor common subunit beta Proteins 0.000 description 1
- 238000006546 Horner-Wadsworth-Emmons reaction Methods 0.000 description 1
- YZCKVEUIGOORGS-UHFFFAOYSA-N Hydrogen atom Chemical class [H] YZCKVEUIGOORGS-UHFFFAOYSA-N 0.000 description 1
- LHSGPCFBGJHPCY-UHFFFAOYSA-N L-leucine-L-tyrosine Natural products CC(C)CC(N)C(=O)NC(C(O)=O)CC1=CC=C(O)C=C1 LHSGPCFBGJHPCY-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- GZGWILAQHOVXTD-DCAQKATOSA-N Lys-Met-Asp Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(O)=O GZGWILAQHOVXTD-DCAQKATOSA-N 0.000 description 1
- 108010047230 Member 1 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- SITLTJHOQZFJGG-UHFFFAOYSA-N N-L-alpha-glutamyl-L-valine Natural products CC(C)C(C(O)=O)NC(=O)C(N)CCC(O)=O SITLTJHOQZFJGG-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000009668 Neurobehavioral Manifestations Diseases 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 1
- 208000027089 Parkinsonian disease Diseases 0.000 description 1
- 206010034010 Parkinsonism Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- GOUWCZRDTWTODO-YDHLFZDLSA-N Phe-Val-Asn Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O GOUWCZRDTWTODO-YDHLFZDLSA-N 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- NCDNCNXCDXHOMX-UHFFFAOYSA-N Ritonavir Natural products C=1C=CC=CC=1CC(NC(=O)OCC=1SC=NC=1)C(O)CC(CC=1C=CC=CC=1)NC(=O)C(C(C)C)NC(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-UHFFFAOYSA-N 0.000 description 1
- YJDYDFNKCBANTM-QCWCSKBGSA-N SDZ PSC 833 Chemical compound C\C=C\C[C@@H](C)C(=O)[C@@H]1N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C(=O)[C@H](C(C)C)NC1=O YJDYDFNKCBANTM-QCWCSKBGSA-N 0.000 description 1
- BRGQQXQKPUCUJQ-KBIXCLLPSA-N Ser-Glu-Ile Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O BRGQQXQKPUCUJQ-KBIXCLLPSA-N 0.000 description 1
- QYBRQMLZDDJBSW-AVGNSLFASA-N Ser-Tyr-Glu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O QYBRQMLZDDJBSW-AVGNSLFASA-N 0.000 description 1
- 229910018557 Si O Inorganic materials 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 108700019146 Transgenes Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 229920004896 Triton X-405 Polymers 0.000 description 1
- CDKZJGMPZHPAJC-ULQDDVLXSA-N Tyr-Leu-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 CDKZJGMPZHPAJC-ULQDDVLXSA-N 0.000 description 1
- FOADDSDHGRFUOC-DZKIICNBSA-N Val-Glu-Phe Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O)N FOADDSDHGRFUOC-DZKIICNBSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- ZKAOSOCMPBXHQJ-GJZGRUSLSA-N [(2r,3s)-4-(3,5-difluorophenyl)-3-[(2-methylpropan-2-yl)oxycarbonylamino]-1-oxobutan-2-yl] acetate Chemical compound CC(C)(C)OC(=O)N[C@H]([C@H](C=O)OC(=O)C)CC1=CC(F)=CC(F)=C1 ZKAOSOCMPBXHQJ-GJZGRUSLSA-N 0.000 description 1
- 230000009102 absorption Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 125000000641 acridinyl group Chemical class C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 150000004808 allyl alcohols Chemical class 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- CBTVGIZVANVGBH-UHFFFAOYSA-N aminomethyl propanol Chemical compound CC(C)(N)CO CBTVGIZVANVGBH-UHFFFAOYSA-N 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 108010064397 amyloid beta-protein (1-40) Proteins 0.000 description 1
- 230000003942 amyloidogenic effect Effects 0.000 description 1
- 206010002022 amyloidosis Diseases 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 229940069428 antacid Drugs 0.000 description 1
- 239000003159 antacid agent Substances 0.000 description 1
- 230000001458 anti-acid effect Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 229940027998 antiseptic and disinfectant acridine derivative Drugs 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229940039856 aricept Drugs 0.000 description 1
- 125000003710 aryl alkyl group Chemical group 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000012131 assay buffer Substances 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- 125000003725 azepanyl group Chemical group 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000002047 benzodioxolyl group Chemical group O1OC(C2=C1C=CC=C2)* 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- WXBLLCUINBKULX-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1.OC(=O)C1=CC=CC=C1 WXBLLCUINBKULX-UHFFFAOYSA-N 0.000 description 1
- 125000004619 benzopyranyl group Chemical group O1C(C=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004622 benzoxazinyl group Chemical group O1NC(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- FFBHFFJDDLITSX-UHFFFAOYSA-N benzyl N-[2-hydroxy-4-(3-oxomorpholin-4-yl)phenyl]carbamate Chemical compound OC1=C(NC(=O)OCC2=CC=CC=C2)C=CC(=C1)N1CCOCC1=O FFBHFFJDDLITSX-UHFFFAOYSA-N 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 229920000249 biocompatible polymer Polymers 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004744 butyloxycarbonyl group Chemical group 0.000 description 1
- 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 229960004424 carbon dioxide Drugs 0.000 description 1
- 238000000114 cell free in vitro assay Methods 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000012822 chemical development Methods 0.000 description 1
- 229940112822 chewing gum Drugs 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 125000002668 chloroacetyl group Chemical group ClCC(=O)* 0.000 description 1
- 239000000544 cholinesterase inhibitor Substances 0.000 description 1
- 125000003016 chromanyl group Chemical group O1C(CCC2=CC=CC=C12)* 0.000 description 1
- 125000004617 chromonyl group Chemical group O1C(=CC(C2=CC=CC=C12)=O)* 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 231100000870 cognitive problem Toxicity 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 239000003636 conditioned culture medium Substances 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 125000000332 coumarinyl group Chemical group O1C(=O)C(=CC2=CC=CC=C12)* 0.000 description 1
- WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 125000005959 diazepanyl group Chemical group 0.000 description 1
- ACYGYJFTZSAZKR-UHFFFAOYSA-J dicalcium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Ca+2].[Ca+2].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O ACYGYJFTZSAZKR-UHFFFAOYSA-J 0.000 description 1
- 125000005992 dihydrobenzisothiazinyl group Chemical group 0.000 description 1
- 125000005993 dihydrobenzisoxazinyl group Chemical group 0.000 description 1
- 125000004852 dihydrofuranyl group Chemical group O1C(CC=C1)* 0.000 description 1
- 125000005046 dihydronaphthyl group Chemical group 0.000 description 1
- 125000005043 dihydropyranyl group Chemical group O1C(CCC=C1)* 0.000 description 1
- 125000005051 dihydropyrazinyl group Chemical group N1(CC=NC=C1)* 0.000 description 1
- 125000005052 dihydropyrazolyl group Chemical group N1(NCC=C1)* 0.000 description 1
- 125000004655 dihydropyridinyl group Chemical group N1(CC=CC=C1)* 0.000 description 1
- 125000005053 dihydropyrimidinyl group Chemical group N1(CN=CC=C1)* 0.000 description 1
- 125000005054 dihydropyrrolyl group Chemical group [H]C1=C([H])C([H])([H])C([H])([H])N1* 0.000 description 1
- 125000005044 dihydroquinolinyl group Chemical group N1(CC=CC2=CC=CC=C12)* 0.000 description 1
- 239000012470 diluted sample Substances 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Natural products O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 description 1
- 229960003135 donepezil hydrochloride Drugs 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 229960001484 edetic acid Drugs 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000003821 enantio-separation Methods 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 238000007824 enzymatic assay Methods 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 239000005038 ethylene vinyl acetate Substances 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 229940108366 exelon Drugs 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000013213 extrapolation Methods 0.000 description 1
- 239000010685 fatty oil Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 108091007739 gamma-secretases Proteins 0.000 description 1
- 102000038383 gamma-secretases Human genes 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 150000004795 grignard reagents Chemical class 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 125000001188 haloalkyl group Chemical group 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 1
- 239000004030 hiv protease inhibitor Substances 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 102000055647 human CSF2RB Human genes 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- USZLCYNVCCDPLQ-UHFFFAOYSA-N hydron;n-methoxymethanamine;chloride Chemical compound Cl.CNOC USZLCYNVCCDPLQ-UHFFFAOYSA-N 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000005462 in vivo assay Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000021005 inheritance pattern Diseases 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 125000005994 isobenzotetrahydrofuranyl group Chemical group 0.000 description 1
- 125000005995 isobenzotetrahydrothienyl group Chemical group 0.000 description 1
- 125000005990 isobenzothienyl group Chemical group 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000003384 isochromanyl group Chemical group C1(OCCC2=CC=CC=C12)* 0.000 description 1
- 125000003151 isocoumarinyl group Chemical group C1(=O)OC(=CC2=CC=CC=C12)* 0.000 description 1
- 125000004594 isoindolinyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000005928 isopropyloxycarbonyl group Chemical group [H]C([H])([H])C([H])(OC(*)=O)C([H])([H])[H] 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 238000011813 knockout mouse model Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 108010012058 leucyltyrosine Proteins 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 231100000863 loss of memory Toxicity 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- QUXHCILOWRXCEO-UHFFFAOYSA-M magnesium;butane;chloride Chemical compound [Mg+2].[Cl-].CCC[CH2-] QUXHCILOWRXCEO-UHFFFAOYSA-M 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 229960004296 megestrol acetate Drugs 0.000 description 1
- RQZAXGRLVPAYTJ-GQFGMJRRSA-N megestrol acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 RQZAXGRLVPAYTJ-GQFGMJRRSA-N 0.000 description 1
- 206010027175 memory impairment Diseases 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960001047 methyl salicylate Drugs 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- YCAXZAOSZRANEC-UHFFFAOYSA-N n-(5-cyano-3,4-dihydroxy-1-phenylpentan-2-yl)-2-[methyl(methylsulfonyl)amino]-1,3-oxazole-4-carboxamide Chemical compound O1C(N(C)S(C)(=O)=O)=NC(C(=O)NC(CC=2C=CC=CC=2)C(O)C(O)CC#N)=C1 YCAXZAOSZRANEC-UHFFFAOYSA-N 0.000 description 1
- GVIFTQAQJODAGI-UHFFFAOYSA-N n-(6-cyano-3,4-dihydroxy-1-phenylhexan-2-yl)-2-[methyl(methylsulfonyl)amino]-1,3-oxazole-4-carboxamide Chemical compound O1C(N(C)S(C)(=O)=O)=NC(C(=O)NC(CC=2C=CC=CC=2)C(O)C(O)CCC#N)=C1 GVIFTQAQJODAGI-UHFFFAOYSA-N 0.000 description 1
- ZPIJWEQMCUXUQY-UHFFFAOYSA-N n-[1-(3,5-difluorophenyl)-3,4-dihydroxynon-8-yn-2-yl]-2-[methyl(methylsulfonyl)amino]-1,3-oxazole-4-carboxamide Chemical compound O1C(N(C)S(C)(=O)=O)=NC(C(=O)NC(CC=2C=C(F)C=C(F)C=2)C(O)C(O)CCCC#C)=C1 ZPIJWEQMCUXUQY-UHFFFAOYSA-N 0.000 description 1
- OSFCMRGOZNQUSW-UHFFFAOYSA-N n-[4-[2-(6,7-dimethoxy-3,4-dihydro-1h-isoquinolin-2-yl)ethyl]phenyl]-5-methoxy-9-oxo-10h-acridine-4-carboxamide Chemical compound N1C2=C(OC)C=CC=C2C(=O)C2=C1C(C(=O)NC1=CC=C(C=C1)CCN1CCC=3C=C(C(=CC=3C1)OC)OC)=CC=C2 OSFCMRGOZNQUSW-UHFFFAOYSA-N 0.000 description 1
- OLKBLJHSTWMWDY-UHFFFAOYSA-N n-[6-cyano-3,4-dihydroxy-1-(4-hydroxyphenyl)hexan-2-yl]-2-[methyl(methylsulfonyl)amino]-1,3-oxazole-4-carboxamide Chemical compound O1C(N(C)S(C)(=O)=O)=NC(C(=O)NC(CC=2C=CC(O)=CC=2)C(O)C(O)CCC#N)=C1 OLKBLJHSTWMWDY-UHFFFAOYSA-N 0.000 description 1
- VKKPNUKKSFMUEK-UHFFFAOYSA-N n-[7-cyano-3,4-dihydroxy-1-(4-hydroxyphenyl)heptan-2-yl]-2-[methyl(methylsulfonyl)amino]-1,3-oxazole-4-carboxamide Chemical compound O1C(N(C)S(C)(=O)=O)=NC(C(=O)NC(CC=2C=CC(O)=CC=2)C(O)C(O)CCCC#N)=C1 VKKPNUKKSFMUEK-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000002159 nanocrystal Substances 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000018791 negative regulation of catalytic activity Effects 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 210000003061 neural cell Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000000508 neurotrophic effect Effects 0.000 description 1
- 239000000346 nonvolatile oil Substances 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 125000002524 organometallic group Chemical group 0.000 description 1
- 239000012285 osmium tetroxide Substances 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 238000005949 ozonolysis reaction Methods 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- HGBOYTHUEUWSSQ-UHFFFAOYSA-N pentanal Chemical compound CCCCC=O HGBOYTHUEUWSSQ-UHFFFAOYSA-N 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 125000001644 phenoxazinyl group Chemical group C1(=CC=CC=2OC3=CC=CC=C3NC12)* 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- 125000005544 phthalimido group Chemical group 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920001467 poly(styrenesulfonates) Polymers 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- 239000004633 polyglycolic acid Substances 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229910000343 potassium bisulfate Inorganic materials 0.000 description 1
- MICLTPPSCUXHJT-UHFFFAOYSA-M potassium;4-[3-(6-oxo-3h-purin-9-yl)propanoylamino]benzoate Chemical compound [K+].C1=CC(C(=O)[O-])=CC=C1NC(=O)CCN1C(NC=NC2=O)=C2N=C1 MICLTPPSCUXHJT-UHFFFAOYSA-M 0.000 description 1
- 230000000063 preceeding effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 229960001404 quinidine Drugs 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000004620 quinolinyl-N-oxide group Chemical group 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
- 238000009790 rate-determining step (RDS) Methods 0.000 description 1
- 229960000311 ritonavir Drugs 0.000 description 1
- NCDNCNXCDXHOMX-XGKFQTDJSA-N ritonavir Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-XGKFQTDJSA-N 0.000 description 1
- 229960004136 rivastigmine Drugs 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 238000009738 saturating Methods 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 108010048818 seryl-histidine Proteins 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 125000003808 silyl group Chemical group [H][Si]([H])([H])[*] 0.000 description 1
- 229960002930 sirolimus Drugs 0.000 description 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
- HELHAJAZNSDZJO-OLXYHTOASA-L sodium L-tartrate Chemical compound [Na+].[Na+].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O HELHAJAZNSDZJO-OLXYHTOASA-L 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- WBHQBSYUUJJSRZ-UHFFFAOYSA-M sodium bisulfate Chemical compound [Na+].OS([O-])(=O)=O WBHQBSYUUJJSRZ-UHFFFAOYSA-M 0.000 description 1
- 229910000342 sodium bisulfate Inorganic materials 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000001433 sodium tartrate Substances 0.000 description 1
- 229960002167 sodium tartrate Drugs 0.000 description 1
- 235000011004 sodium tartrates Nutrition 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 238000011895 specific detection Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 229960001603 tamoxifen Drugs 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- GBOBNAVUSIITJY-YESZJQIVSA-N tert-butyl n-[(2s,3r,4s)-3,4-dihydroxy-6-methyl-1-phenylheptan-2-yl]carbamate Chemical compound CC(C)C[C@H](O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)CC1=CC=CC=C1 GBOBNAVUSIITJY-YESZJQIVSA-N 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000003039 tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 1
- 125000005329 tetralinyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 229950010938 valspodar Drugs 0.000 description 1
- 108010082372 valspodar Proteins 0.000 description 1
- 108010073969 valyllysine Proteins 0.000 description 1
- 150000003681 vanadium Chemical class 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 229960001722 verapamil Drugs 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 235000012431 wafers Nutrition 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 238000010626 work up procedure Methods 0.000 description 1
- IHOVFYSQUDPMCN-QKUIIBHLSA-N zosuquidar Chemical compound C([C@H](COC=1C2=CC=CN=C2C=CC=1)O)N(CC1)CCN1C1C2=CC=CC=C2C2C(F)(F)C2C2=CC=CC=C12 IHOVFYSQUDPMCN-QKUIIBHLSA-N 0.000 description 1
- 125000004933 β-carbolinyl group Chemical group C1(=NC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
- C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C215/22—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated
- C07C215/28—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/70—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/84—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
- C07C255/32—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring
- C07C255/42—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being further bound to other hetero atoms
- C07C255/44—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being further bound to other hetero atoms at least one of the singly-bound nitrogen atoms being acylated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
- C07C323/39—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton at least one of the nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom
- C07C323/40—Y being a hydrogen or a carbon atom
- C07C323/42—Y being a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/48—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/50—Nitrogen atoms bound to hetero atoms
- C07D277/52—Nitrogen atoms bound to hetero atoms to sulfur atoms, e.g. sulfonamides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Pyridine Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29782701P | 2001-06-13 | 2001-06-13 | |
| US60/297,827 | 2001-06-13 | ||
| US33308401P | 2001-11-19 | 2001-11-19 | |
| US60/333,084 | 2001-11-19 | ||
| PCT/US2002/018845 WO2002100818A2 (en) | 2001-06-13 | 2002-06-13 | Aminediols as agents for the treatment of alzheimer's disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2450205A1 true CA2450205A1 (en) | 2002-12-19 |
Family
ID=26970331
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002450205A Abandoned CA2450205A1 (en) | 2001-06-13 | 2002-06-13 | Aminediols for the treatment of alzheimer's disease |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US6906104B2 (enExample) |
| EP (1) | EP1395251A2 (enExample) |
| JP (1) | JP2004532894A (enExample) |
| AU (1) | AU2002315131A1 (enExample) |
| CA (1) | CA2450205A1 (enExample) |
| MX (1) | MXPA03011521A (enExample) |
| WO (1) | WO2002100818A2 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7695919B2 (en) * | 2001-05-10 | 2010-04-13 | Battelle Energy Alliance, Llc | Antibody profiling sensitivity through increased reporter antibody layering |
| USRE44031E1 (en) | 2001-05-10 | 2013-02-26 | Battelle Energy Alliance, Llc | Antibody profiling sensitivity through increased reporter antibody layering |
| US6989276B2 (en) | 2001-05-10 | 2006-01-24 | Battelle Energy Alliance, Llc | Rapid classification of biological components |
| USRE46351E1 (en) | 2001-05-10 | 2017-03-28 | Battelle Energy Alliance, Llc | Antibody profiling sensitivity through increased reporter antibody layering |
| BR0214293A (pt) * | 2001-11-19 | 2005-04-19 | Upjohn Co | Composto e métodos para tratar um paciente que tenha, ou de prevenir um paciente de adquirir, uma doença ou condição e para produzir um composto ou um sal ou éster farmaceuticamente aceitável do mesmo |
| EP1534693A2 (en) * | 2002-09-06 | 2005-06-01 | Elan Pharmaceuticals, Inc. | 1, 3-diamino-2-hydroxypropane prodrug derivatives |
| US7521481B2 (en) * | 2003-02-27 | 2009-04-21 | Mclaurin Joanne | Methods of preventing, treating and diagnosing disorders of protein aggregation |
| CA2445420A1 (en) | 2003-07-29 | 2005-01-29 | Invitrogen Corporation | Kinase and phosphatase assays |
| US7619059B2 (en) | 2003-07-29 | 2009-11-17 | Life Technologies Corporation | Bimolecular optical probes |
| US7727752B2 (en) * | 2003-07-29 | 2010-06-01 | Life Technologies Corporation | Kinase and phosphatase assays |
| US20070196860A1 (en) * | 2006-01-18 | 2007-08-23 | Invitrogen Corporation | Methods for Measuring Real Time Kinase Activity |
| US20080286881A1 (en) * | 2007-05-14 | 2008-11-20 | Apel William A | Compositions and methods for combining report antibodies |
| US8351674B2 (en) * | 2007-05-31 | 2013-01-08 | Battelle Energy Alliance, Llc | Image portion identification methods, image parsing methods, image parsing systems, and articles of manufacture |
| US8962677B2 (en) * | 2007-07-12 | 2015-02-24 | Acumen Pharmaceuticals, Inc. | Methods of restoring cognitive ability using non-peptidic compounds |
| US20110098309A1 (en) * | 2007-07-12 | 2011-04-28 | Acumen Pharmaceuticals, Inc. | Methods of inhibiting the formation of amyloid-beta diffusable ligands using acylhydrazide compounds |
| US9006283B2 (en) | 2007-07-12 | 2015-04-14 | Acumen Pharmaceuticals, Inc. | Methods of modifying amyloid β oligomers using non-peptidic compounds |
| WO2009051661A2 (en) * | 2007-10-12 | 2009-04-23 | The Brigham And Women's Hospital, Inc. | Substituted aryl alkylamino-oxy-analogs and uses thereof |
| CA2707309A1 (en) | 2007-12-18 | 2009-06-25 | Acumen Pharmaceuticals, Inc. | Novel addl receptor polypeptides, polynucleotides and host cells for recombinant production |
| US9410965B2 (en) * | 2009-09-17 | 2016-08-09 | Battelle Energy Alliance, Llc | Identification of discriminant proteins through antibody profiling, methods and apparatus for identifying an individual |
| US8969009B2 (en) * | 2009-09-17 | 2015-03-03 | Vicki S. Thompson | Identification of discriminant proteins through antibody profiling, methods and apparatus for identifying an individual |
| CN118047698A (zh) * | 2024-01-30 | 2024-05-17 | 山东科巢生物制药有限公司 | 一种n-[(1r)-2-[1,1'-联苯]-4-基-1-(羟基甲基)乙基]氨基甲酸叔丁酯的制备方法 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US5721131A (en) | 1987-03-06 | 1998-02-24 | United States Of America As Represented By The Secretary Of The Navy | Surface modification of polymers with self-assembled monolayers that promote adhesion, outgrowth and differentiation of biological cells |
| US5912410A (en) | 1990-06-15 | 1999-06-15 | Scios Inc. | Transgenic non-human mice displaying the amyloid-forming pathology of alzheimer's disease |
| WO1991019810A1 (en) | 1990-06-15 | 1991-12-26 | California Biotechnology Inc. | Transgenic non-human mammal displaying the amyloid-forming pathology of alzheimer's disease |
| WO1992013069A1 (en) | 1991-01-21 | 1992-08-06 | Imperial College Of Science, Technology & Medicine | Test and model for alzheimer's disease |
| US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
| WO1993014200A1 (en) | 1992-01-07 | 1993-07-22 | Tsi Corporation | Transgenic animal models for alzheimer's disease |
| US5604102A (en) | 1992-04-15 | 1997-02-18 | Athena Neurosciences, Inc. | Methods of screening for β-amyloid peptide production inhibitors |
| US5441870A (en) | 1992-04-15 | 1995-08-15 | Athena Neurosciences, Inc. | Methods for monitoring cellular processing of β-amyloid precursor protein |
| US5766846A (en) | 1992-07-10 | 1998-06-16 | Athena Neurosciences | Methods of screening for compounds which inhibit soluble β-amyloid peptide production |
| US5399763A (en) * | 1993-02-01 | 1995-03-21 | Nippon Kayaku Kabushiki Kaisha | Process for preparing optically active 2-aminopropanal |
| IL110525A0 (en) * | 1993-08-09 | 1994-11-11 | Lilly Co Eli | Identification and use of protease inhibitors |
| PT730643E (pt) | 1993-10-27 | 2001-06-29 | Lilly Co Eli | Animais transgenicos portadores do alelo de app com mutacao sueca |
| US5877399A (en) | 1994-01-27 | 1999-03-02 | Johns Hopkins University | Transgenic mice expressing APP-Swedish mutation develop progressive neurologic disease |
| US5728718A (en) * | 1994-12-20 | 1998-03-17 | The United States Of America As Represented By The Department Of Health And Human Services | 2,5-diamino-3,4-disubstituted-1,6-diphenylhexane isosteres comprising benzamide, sulfonamide and anthranilamide subunits and methods of using same |
| US5744346A (en) | 1995-06-07 | 1998-04-28 | Athena Neurosciences, Inc. | β-secretase |
| EP0871720A2 (en) | 1995-06-07 | 1998-10-21 | Athena Neurosciences, Inc. | Beta-secretase, antibodies to beta-secretase, and assays for detecting beta-secretase inhibition |
| US5763464A (en) * | 1995-11-22 | 1998-06-09 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Retroviral agents containing anthranilamide, substituted benzamide and other subunits, and methods of using same |
| DK0948630T3 (da) | 1996-11-20 | 2008-08-11 | Oklahoma Med Res Found | Kloning og karakterisering af napsin, en asparaginprotease |
| US6191166B1 (en) | 1997-11-21 | 2001-02-20 | Elan Pharmaceuticals, Inc. | Methods and compounds for inhibiting β-amyloid peptide release and/or its synthesis |
| US6045829A (en) | 1997-02-13 | 2000-04-04 | Elan Pharma International Limited | Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers |
| US5962506A (en) * | 1997-07-07 | 1999-10-05 | Pharmacopeia, Inc. | Glycol and hydroxyphosphonate peptidomimetics as inhibitors of aspartyl proteases |
| GB9812189D0 (en) | 1998-06-05 | 1998-08-05 | Glaxo Group Ltd | Methods and compositions for increasing penetration of HIV protease inhibitors |
| WO2000003819A1 (en) | 1998-07-17 | 2000-01-27 | The Penn State Research Foundation | Full form roll finishing technique |
| CZ2001966A3 (cs) | 1998-09-24 | 2001-10-17 | Pharmacia & Upjohn Company | Sekretasa spojená s Alzheimerovou chorobou |
| WO2000030190A1 (en) * | 1998-11-17 | 2000-05-25 | C & D Technologies, Inc. | Selectable capacity fixed footprint lead-acid battery racking system with horizontal plates |
| CA2359785A1 (en) | 1999-02-10 | 2000-08-17 | John P. Anderson | .beta.-secretase enzyme compositions and methods |
| EP1202737A4 (en) | 1999-08-09 | 2005-03-02 | Univ Vanderbilt | USE OF P-GLYCOPROTEIN MODULATORS IN ANTIVIRAL TREATMENT |
| AU782312B2 (en) | 1999-09-23 | 2005-07-21 | Pharmacia & Upjohn Company | Alzheimer's disease secretase, APP substrates therefor, and uses therefor |
| JP2002370183A (ja) * | 2001-06-15 | 2002-12-24 | Yamaha Motor Co Ltd | 監視装置及び監視システム |
-
2002
- 2002-06-13 MX MXPA03011521A patent/MXPA03011521A/es not_active Application Discontinuation
- 2002-06-13 AU AU2002315131A patent/AU2002315131A1/en not_active Abandoned
- 2002-06-13 EP EP02742074A patent/EP1395251A2/en not_active Withdrawn
- 2002-06-13 JP JP2003503588A patent/JP2004532894A/ja active Pending
- 2002-06-13 CA CA002450205A patent/CA2450205A1/en not_active Abandoned
- 2002-06-13 WO PCT/US2002/018845 patent/WO2002100818A2/en not_active Ceased
- 2002-06-13 US US10/171,343 patent/US6906104B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| WO2002100818A2 (en) | 2002-12-19 |
| MXPA03011521A (es) | 2004-03-18 |
| US20030092747A1 (en) | 2003-05-15 |
| AU2002315131A1 (en) | 2002-12-23 |
| US6906104B2 (en) | 2005-06-14 |
| EP1395251A2 (en) | 2004-03-10 |
| JP2004532894A (ja) | 2004-10-28 |
| WO2002100818A3 (en) | 2003-09-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6864290B2 (en) | Statine derivatives for the treatment of Alzheimer's disease | |
| US7244755B2 (en) | Hydroxypropylamines | |
| US6962934B2 (en) | Substituted amino carboxamides for the treatment of Alzheimer's disease | |
| CA2461603A1 (en) | Substituted amines for the treatment of neurological disorders | |
| CA2450205A1 (en) | Aminediols for the treatment of alzheimer's disease | |
| US20030083353A1 (en) | Diaminediols for the treatment of Alzheimer's disease | |
| US20040039034A1 (en) | Hydroxypropyl amides for the treatment of Alzheimer's disease | |
| CA2498269A1 (en) | Substituted aminoethers for the treatment of alzheimer's disease | |
| US7053109B2 (en) | Aminediols for the treatment of Alzheimer's disease | |
| US7763646B2 (en) | Compounds for the treatment of alzheimer's disease | |
| CA2543756A1 (en) | Hydroxypropyl amides for the treatment of alzheimer's disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued | ||
| FZDE | Discontinued |
Effective date: 20100614 |